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ABSTRACT
DONEPEZIL’S EFFECT ON CARDIAC FUNCTION IN PATIENTS WITH
ALZHEIMER’S DISEASE THROUGH AN IN VIVO, NON INVASIVE MEASURE
OF CARDIAC AUTONOMIC FUNCTION
Lewis Patrick Hackett
Old Dominion University, 2015
Director: Dr. Serina A. Neumann

The aim of the current study was to explore the effects of the medication
Donepezil (Aricept®) on cardiac autonomic function for individuals diagnosed with mild
to moderate (probable) Alzheimer’s disease (AD). Using age (± 3 years) and gender
matched controls, differences in heart rate variability (HRV) among individuals with
Alzheimer’s disease were compared to healthy controls over a period of six months
(session 1 [baseline], session 2 [3 months], and session 3 [6 months]) in both supine and
standing positions. HRV was obtained through frequency-domain (Low Frequency
Power, High Frequency Power, RMSSD, LF/HF Ratio) and time-domain (six minutes)
measures using ECG technology. Data were analyzed using 2x2x2 (AD group n= 12; HC
group n= 12) and 2x2x3 (AD group n= 8; HC group n= 8) repeated measures
ANCOVA’s while controlling for age, gender, body mass index (BMI), blood pressure,
medications, dose of Donepezil (Aricept®), alcohol use, caffeine use, and physical
activity. Results from the ANCOVA did not reveal statistically significant between group
differences for the HRV frequency-domain measures. However, data indicated a trend
towards greater reductions in normalized high frequency power (parasympathetic
depression) and greater increases in normalized low frequency power (sympathetic
exacerbation) among the AD group versus healthy controls at all three time points despite
the use of Donepezil (Aricept®).

Keywords: heart rate variability, cholinesterase inhibitor, Alzheimer’s disease
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This dissertation is dedicated to the geropsychology community and all persons who are
committed to improving the life and well-being of the aging population.
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CHAPTER I
INTRODUCTION
The aim of the current study was to explore the effects of the medication
Donepezil (Aricept®) on cardiac autonomic function for individuals diagnosed with
Alzheimer’s disease (AD) and taking the medication Donepezil (Aricept®). Donepezil is
a widely used cholinesterase inhibitor (ChEls) that is designed to increase cholinergic
function among persons with mild to moderate AD. Cholinergic function regulates
cardiac autonomic activity via the sympathetic nervous system (SNS) and the
parasympathetic nervous system (PNS). Cholinergic function also plays an integral role
in neurocognitive function. Depletion of cholinergic resources often results in cardiac
autonomic dysfunction and neurocognitive impairment in persons with AD (Allan et al.,
2006; Bartus, 1999; Giubilei, et al., 1998; Toledo & Junqueira, 2008, 2009; Zulli et al.,
2005). Cardiac autonomic dysfunction generally refers to the imbalance of the
sympathetic and parasympathetic nervous system. This imbalance is a recognized risk
factor for cardiovascular mortality, characterized by higher risk of arrhythmias,
parasympathetic depression, syncope, and sudden death (Allan et al., 2007; Kleiger,
Miller, Bigger, & Moss, 1986; Schliebs & Arendt, 2006). Previous research has indicated
some potential cardio-protective benefits of taking the medication Donepezil, and this is
of particular interest in the present study.
As research has demonstrated that individuals with AD often present with cardiac
autonomic dysfunction, a growing body of evidence has supported the use of heart rate
variability (HRV) measures in identifying cardiac autonomic dysfunction in persons with
AD (Allan et al., 2007; Balocchi et al., 2006; Da Costa Dias Dias, Da Silva, De Moraes,
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& Caramelli, 2013; Giubilei et al., 1998; Masuda & Kawamura, 2003; McLaren, Allen,
Murray, Ballard, & Kenny, 2003; Siepmann, Mück, Engel, Rupprecht, & MückWeymann, 2006; Task Force on Heart Rate Variability, 1996; Zulli et al., 2005). Heart
rate variability (HRV) is frequently measured using non-invasive electrocardiogram
(ECG) technology. This typically involves the patient wearing a heart rate sensor
positioned close to the heart and a receiver is then positioned in close proximity to the
sensor. In its most basic form, HRV refers to the fluctuation of intervals between
consecutive heart beats as well as the fluctuation between consecutive instantaneous heart
rates (Task Force on Heart Rate Variability, 1996). The HRV algorithm is not necessarily
a measure of heart beats, but is rather a measure of the time and variation between beats
(Task Force on Heart Rate Variability, 1996). This variation between beats is referred to
as inter beat interval and is measured in milliseconds (ms). HRV more generally
describes the variations in both heart beat intervals (RR intervals) and heart rate cycles
(instantaneous heart rate) over a designated time frame. It is the variations in HRV
intervals that are of particular interest here, as they represent changes in cardiac
autonomic activity (Bernardi et al., 2011).
Using HRV technology, frequency-domain and time-domain (e.g., six minutes)
measures can be used to provide an algorithm that represents cardiac autonomic output.
ECG technology provides frequencies that reflect different levels of cardiac outflow and
these include; very low frequency (0–0.04 Hz), low frequency (0.04–0.15 Hz), and high
frequency (0.15–0.50 Hz) spectral bands. Low frequency (LF) output provides a measure
of sympathetic and parasympathetic nervous activity, while high frequency (HF) output
provides an exclusive measure of parasympathetic (cholinergic) nervous activity (Allan et
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al., 2007; Task Force on Heart Rate Variability, 1996). In addition to this, the LF/HF
ratio is computed and can be used as a measure of sympathovagal balance to reflect
sympathetic modulation (Task Force on Heart Rate Variability, 1996). Frequency-domain
measures have yielded significant results in a number of studies looking at cardiac
autonomic function in persons with AD (Allan et al., 2007; Da Costa Dias et al., 2013;
Giubilei et al., 1998; Masuda & Kawamura, 2003; Umegaki & Khookhor, 2013; Zulli et
al., 2005). The most commonly used time-domain measure includes the mean squared
differences of successive R-R intervals (RMSSD). This is used as a measurement to
estimate the high frequency variations in heart rate (Toledo & Junqueira, 2008). It is
commonly perceived that a regular heartbeat is a sign of strong cardiovascular health.
However, the rhythm of a healthy heart or the successive cardiac cycle length is
characterized by significant variability in healthy individuals. Therefore, normal and
healthy heart rate is characterized by more variability and reductions in variability are
often indicative of disease conditions (Sharma, Paudel, Singh, & Limbua, 2009). More
specifically, greater high frequency (HF) HRV is an indicator of more healthful cardiac
autonomic functioning, and those with AD tend to present with lower high frequency
(HF) output (or parasympathetic depression; Sharma, Paudel, Singh, & Limbua, 2009;
Toledo & Junqueira, 2008).
The aim of the present study is to not only explore the differences in cardiac
autonomic function in persons with AD compared to healthy controls, but to also explore
the effects of the cholinesterase inhibitor (ChEl) Donepezil on cardiac autonomic
function. Research has indicated potential cardiac autonomic benefits when using the
popular cholinesterase inhibitor Donepezil (Nordstrom, Religa, Wimo, Winblad, &
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Eriksdotter, 2013; Umegaki & Khookhor, 2013). The medication Donepezil
hydrochloride (Aricept®) is one of the most popular ChEls used to treat cognitive
impairment among persons with AD. ChEls such as Donepezil operate by preventing
acetylcholine from being hydrolyzed thus increasing cholinergic resources. As
cholinergic transmission is a mechanism involved in the regulation of the autonomic
nervous system, it is hypothesized that Donepezil may provide some additional cardioprotective benefits. These cardio-protective benefits can be assessed through changes in
HRV as measured by ECG technology.
Previous research has identified differences in cardiac autonomic function
between individuals with AD versus healthy controls. Toledo & Junqueira (2008) and
Zulli et al (2005) monitored cardiac autonomic function via ECG technology among
those with AD, but in the absence of ChEl treatment. Both authors found significant
differences in HRV between AD participants and healthy controls such that those with
AD demonstrated parasympathetic depression (suggesting lower cholinergic function) in
comparison to healthy controls. The authors of both studies assessed HRV at a single,
fixed, time frame. The present study however, will extend the research from a single,
fixed, time frame to look at changes in HRV over a period of six months. HRV data will
be obtained at three different time points; baseline (session 1), and at three (session 2)
and six month (session 3) follow-up intervals. Despite the single time-frame (cross
sectional) design in the previous work, studies support the need for further investigation
into cardiac autonomic dysfunction in persons with AD and support the use of ECG
technology in obtaining HRV data.
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Previous research has also shown that Donepezil stabilizes HRV among
participants with AD by increasing parasympathetic nervous activity and decreasing
sympathetic nervous activity (Giubilei, 1998; Umegaki & Khookhor, 2013). Giubilei et al
(1998) explored the effects of a now discontinued and no longer available cholinesterase
inhibitor (eptastigmine) on cardiac autonomic function via ECG technology over a period
of one month. Participants included 12 individuals who were diagnosed with probable
AD and 10 healthy controls. The AD group participants were prescribed the
cholinesterase inhibitor (eptastigmine) for one month. HRV recordings were obtained
before and after ChEl treatment in both resting and tilting positions. The tilting position is
often used to study heart rate abnormalities by positioning the participant at different
angles (e.g., 90 degrees; Kochiadakis, et al., 1998). This change in positioning often
causes a decrease in high frequency (HF) HRV and subsequent vasovagal syncope (lightheadedness; Efremov, Brisinda, Venuti, & Iantorno, 2015). Results from the study
indicated that both low and high frequency power generated by the AD group in the
tilting position were similar to that of healthy controls following one month of ChEl
treatment. However, major limitations to this study include the use of a now discontinued
ChEls. According to the Alzheimer’s Association (2013), eptastigmine was discontinued
by the Food and Drug Administration (FDA) due to its potentially harmful hematologic
(blood related) adverse effects. This included reductions in red and white blood cells
(pancytopenia) and the development of granulocytopenia (abnormally low concentration
of granulocytes in the blood; Braida & Sala, 2001). Therefore, this medication is no
longer available for use. The lack of FDA approval and negative side-effects associated
with the medication certainly undermine its treatment efficacy and this is a limitation of
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the study. Nonetheless, this study demonstrates some of the potential cardiac benefits
associated with ChEl treatment.
Additional limitations of the Giubilei et al (1998) study include the limited time
frame in which HRV was monitored (one month). Previous studies have indicated that
the benefits of Donepezil tend to be more evident after six weeks of ingestion. For
example, a study by Rogers et al (1998) looked at changes in cognitive function over a
period of 24 weeks (six months) among those with mild to moderate AD who were
treated with Donepezil versus placebo-controls. At six weeks of using the medication, the
authors reported no significant differences between those taking Donepezil versus healthy
controls. However, after six weeks, cognitive performance for the Donepezil-treated
participants improved with time whereas the placebo group showed significant
deterioration (Rogers, 1998). According to the author, the beneficial effects of Donepezil
were most pronounced at the 12 week visit and these effects persisted with no decrease in
magnitude at weeks 18 and 24 (Roger, 1998). Other researchers have also demonstrated
greater gains in cognitive function with Donepezil use after 24 weeks (six months; Mohs
et al., 2001) while other researchers have identified more immediate gains in cognitive
function (Feldman, 2001; Umegaki & Khookhor, 2013). The present study will explore
changes in HRV among persons with AD who are taking Donepezil versus healthy
controls over a period of six months. Participants’ HRV will be recorded at baseline and
at three month and six month time points, for a total of three sessions. Each session must
be within one to two weeks of the three month mark. Therefore, each session occurs
every three months (± two weeks). Based on the research by Feldman, 2001; Mohs et al.,
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2001; Rogers, 1998), this will provide more than adequate time for Donepezil to reach a
therapeutic dose.
Results from these aforementioned studies suggest positive gains in cognitive
function as a result of taking Donepezil which may also reflect an increase in cholinergic
function. As cholinergic function influences both cognitive function and cardiac
autonomic function, it is probable that HRV may also improve more significantly at six
months of taking the medication. Thirdly, although the authors used the tilting position to
measure HRV as recommended by the Task Force on Heart Rate Variability (1996), LF
and HF indices have been shown to change in different positions and under different
conditions such as sitting to standing (Risk, Broadbridge, & Cohen, 2001; Task Force on
Heart Rate Variability, 1996). Obtaining HRV readings from a still resting position
(supine) to a standing position (orthostatic challenge) can help to identify any significant
changes in SNS and PNS activity (Aysin & Aysin, 2007; Risk, Broadbridge, & Cohen,
2001). The present study will employ two commonly used and recommended resting
positions when measuring HRV (supine and standing), and will utilize the participants
respiration when calculating HF HRV (Aysin & Aysin, 2007; Risk, Broadbridge, &
Cohen, 2001; Task Force on Heart Rate Variability, 1996). The adjustment using
respiration in a HRV algorithm is known as respiratory sinus arrhythmia (RSA). The
RSA integrates changes in heart rate during inhalation (heart rate increases) and
exhalation (heart rate decreases). Respiratory linked variations in heart rate usually occur
in the high frequency (HF) range (Lehrer, Vaschillo, and Vaschillo, 2000). RSA has been
shown to provide a more accurate index of cardiac vagal tone and parasympathetic
activity (Grossman & Taylor, 2006).
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In contrast to the Giubilei et al (1998) study, Masuda & Kawamura (2003)
explored changes in HRV using a 24-hour ECG among individuals diagnosed with AD
and who were taking the medication Donepezil for six weeks. The participants were
initially taking 3mg of Donepezil which was later titrated to 5mg (after one week) and
remained at this dose for six weeks. Results from the study indicated reductions in LF
and HF power as a result of Donepezil treatment six weeks after beginning the
medication. The reduction in the HF component was also greater than the reduction in the
LF component, indicating a decrease in PNS activity (and reduced cholinergic activity)
over the period of six weeks despite taking Donepezil. These findings suggest that taking
Donepezil for six weeks did not improve HRV among persons taking the medication.
There are however several methodological limitations to this study. Firstly, the time
frame in which HRV was monitored (six weeks) is fairly short. As mentioned earlier,
studies have indicated that cognitive improvement appears to take place after six weeks
and continues to show therapeutic efficacy at six months (Rogers, 1998; Mohs, 2001).
This suggests Donepezil requires at least six weeks in order to fully metabolize (Rogers,
1998; Mohs et al., 2001). Secondly, participants were provided with a 3mg dose of
Donepezil followed by a 5mg dose for six weeks. It is recommended that persons taking
Donepezil start at a 5mg dose and titrate to a 10 mg dose (the therapeutic dose) after four
to six weeks. Thirdly, participants HRV data was recorded using a 24-hour ECG while
engaging in daily activities. This is problematic, as monitoring HRV while engaging in
activities has been shown to cause variable oscillations in blood pressure creating
interference or “noise” which may reduce accuracy (Gianfrance, Saul, Di Rienzo, &
Mancia, 1994).
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The present study will include participants who are taking both 5mg and 10mg
doses of Donepezil as recommended by pharmacological studies (Feldman et al., 2001).
Fourthly, respiration count was not factored into the HRV algorithm in this previous
work. Obtaining a respiration count and incorporating this into the HRV algorithm is
important for purposes of accuracy, particularly when measuring HF HRV
(parasympathetic activity; Grossman & Taylor, 2006). Lastly, Masuda & Kawamura
(2003) did not use normalized units (n.u.) when analyzing and reporting their HRV
frequency data (LF, HF, and LF/HF). According to the Task Force on Heart Rate
Variability (1996), measurement of LF and HF Power components are typically measured
in absolute values of power (ms2) but LF and HF can also be measured in normalized
units (n.u.). Using normalized units (n.u.) emphasizes changes in sympathetic and
parasympathetic regulation by minimizing the effects of Very Low Frequency power.
Normalized units display sympathetic and parasympathetic activity as a percentage,
allowing the clinician to more easily gauge sympathetic versus parasympathetic
dominance. The advantage of using normalized units surrounds the emphasis on the
controlled and balanced behavior of the sympathetic and parasympathetic nervous
system. Normalized units are also advantageous for tracking changes over time (e.g.,
when using a repeated measures design). Additionally, the normalization process
expresses the quantities more easily by using percentage values (0%-100%).
Normalization also reduces most of the large within and across-subject variability in the
total raw HRV spectral power (Burr, 2007).
The present study proposes the following three hypotheses: 1) participants that are
diagnosed with mild to moderate AD and who are taking a stable dose of Donepezil
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(Aricept®) will show increased parasympathetic nervous activity over a period of six
months. This will be indicated by decreases in LF Power (n.u.) and LF/HF Ratio in the
standing position at session 3 (six months) compared to session 1 (baseline). Thus, there
will be a decrease in LF Power (n.u.) and LF/HF Ratio from session 1 (baseline) to
session 3 (six months) when engaging in the orthostatic challenge (supine to standing). In
contrast, HF Power (n.u.) and RMSSD will increase in the standing position at session 3
(six months) compared to session 1 (baseline). Therefore, there will be an increase in HF
Power (n.u.) and RMSSD from session 1 (baseline) to session 3 (six months) when
engaging in the orthostatic challenge (supine to standing); 2) Healthy controls will show
significant increases in HF Power (n.u.) from a supine to standing position at all three
HRV recorded sessions (baseline, 3 months, and 6 months). The AD group will
demonstrate minimal change in HF Power (n.u.) from a supine to a standing position at
the baseline session, but will show increased HF Power (n.u.) from supine to standing at
sessions 2 and 3. Changes in HF Power (n.u.) from a supine to a standing position at
session 3 will be similar among both AD participants and healthy controls; and 3)
Donepezil (Aricept®) will improve parasympathetic nervous activity through increased
acetylcholine transmission, thus supporting the medication’s use as a potential protective
agent against cardiac autonomic dysfunction.
Currently, research examining cardiac cholinergic function among individuals
with AD using Donepezil is limited. Implications of the current study include the
potential utilization of Donepezil as a protective agent for those experiencing cardiac
autonomic dysfunction. Early detection of parasympathetic depression among persons
with AD and the prescription of Donepezil may help safeguard against a future cardiac
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event such as bradycardia, arrhythmias, transient ischemic attack (TIA), myocardial
infarct, or sudden death.
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CHAPTER II
LITERATURE REVIEW
This chapter will outline research surrounding AD pathology, AD risk factors,
cholinergic and cardiac autonomic function, the treatment efficacy of Donepezil
(Aricept®), heart rate variability (HRV) and the significance of the presenting topic.
Alzheimer’s Disease (AD)
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is
characterized by neuropsychological, neuropsychiatric and neurological symptoms. AD is
the most common cause of dementia and currently affects over five million US
Americans aged 65 and older (Alzheimer’s Association, 2013; Center for Disease
Control, 2013). By 2025, it is estimated that the number of people aged 65 and older with
AD will reach a staggering 7.1 million. In 2012, caregivers provided approximately 17
billion hours of unpaid care to persons with AD, and caregiver stress related to AD care
is becoming increasingly problematic (Alzheimer’s Association, 2013). Typically, AD is
diagnosed when the individual meets a set diagnostic criteria as provided by the
American Psychiatric Association’s Diagnostic and Statistical Manual of Mental
Disorders Fifth Edition (DSM-5).
According to the DSM-5, in order to make a diagnosis of AD, the individual must
meet criteria for either a “minor” or “major” neurocognitive disorder (5th ed., DSM–5;
American Psychiatric Association, 2013). A person who meets criteria for a major
neurocognitive disorder must present with evidence of significant cognitive decline from
a previous level of functioning in one or more of the following cognitive domains:
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complex attention, executive functioning, learning and memory, language, perceptualmotor, or social cognition (5th ed., DSM–5; American Psychiatric Association, 2013).
This evidence must be based on the concern or knowledge of an informant, or there must
be strong evidence of cognitive impairment as revealed by neuropsychological testing.
The cognitive impairment must also interfere with the person’s ability to carry out
activities of daily living (e.g., paying bills or managing medications), and cannot be the
direct result of delirium or a severe mental illness (e.g., major depressive disorder). A
diagnosis of mild neurocognitive disorder is assigned if the individual only exhibits mild
to moderate cognitive decline in the same categories (5th ed., DSM-5; American
Psychiatric Association, 2013).
Once the criteria for a minor or major neurocognitive disorder has been satisfied,
the individual must meet additional diagnostic criteria in order to be diagnosed with AD.
The likelihood of this diagnosis as being “possible” or “probable” is also specified in
accordance with accumulated evidence. The diagnostic criteria required to determine
major and probable AD should include one or more of the following: an insidious or
progressive onset, evidence of causative AD based on genetic evidence, clear evidence of
memory decline, learning and decline in at least one other cognitive domain (as
determined by neuropsychological testing), and a steady progressive or gradual decline in
cognition. Finally, the change in cognition should not be the direct result of another
condition such as cerebrovascular disease. A “possible” specifier is allocated if the
evidence of AD is limited e.g., neuropsychological assessment data is absent but the
patient displays AD features. A “probable” specifier is allocated if there is causative
evidence of AD (e.g., as revealed by genetic testing). Lastly, mild AD is determined
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based on similar criteria but the individual must display only mild to moderate symptoms
(5th ed., DSM-5; American Psychiatric Association, 2013). A “possible” or “probable”
specifier is assigned in a similar fashion as with major AD.
AD is an insidious disease that presents with both positive and negative
neuropathological features. These neuropathological features include both amyloid
plaques and neurofibrillary tangles. These amyloid plaques (Aβ) and neurofibrillary
tangles (NFT’s) were first described by Alois Alzheimer at the turn of the century
following autopsies of a 51-year-old woman and 50-year-old man both of whom had
dementia (Muir, 1996). The classic positive symptoms of AD include the presence of
extracellular amyloid plaque deposits, neurofibrillary tangles (NFT’s), and neuropil
threads (Nitsch, Slack, Wurtman, & Growdon, 1992; Serrano-Pozo, Frosch, Masliah &
Hyman, 2011). Amyloid plaques are characterized by an accumulation of the amyloid-β
peptide (Aβ) which is generated from the amyloid precursor protein (APP; Bertram &
Tanzi, 2008). Neurofibrillary tangles in contrast, contain ribbon-like collections of tau
proteins. Neuropil threads often accompany neurofibrillary tangles, and are thought to be
the result of the breakdown of cell dendrites and axons that are constricted by the NFT’s.
The topographic distribution of amyloid plaques originates in the basal areas of
the frontal, temporal, and occipital lobe, but as the disease progresses, amyloid deposits
can be found in the thalamus and hypothalamus (Braak & Braak, 1991). The distribution
of NFT’s are more widespread than amyloid plaques, with the degeneration beginning in
the allocortex of the medial temporal lobe, and later spreading to the isocortical region
(Serrano-Pozo, Frosch, Masliah & Hyman, 2011). Neurodegenerative studies attribute the
build-up of these plaques and tangles to the process of protein oligomarization. Protein

15

oligomarization occurs when certain neuronal proteins which are typically soluble (e.g.,
tau and α-synuclein), pathologically fold and oligomerize resulting in a type of protein
meld (Selkoe, Mandelkow & Holtzman, 2012). This process of abnormal protein folding
(or oligomarization) underscores the disease-like nature of AD.
In contrast to the positive features of the disease, negative features primarily
include neuronal and synaptic loss (Serrano-Pozo, Frosch, Masliah & Hyman, 2011).
Neuronal loss is the main cause of cortical atrophy, and there are two main factors that
result in neuronal death. Firstly, NFT’s occur within the neuron and displace the cell
nucleus resulting in cell death. These tangle-bearing neurons (also known as “ghost
tangles”) are identified by the appearance of a vacant nucleus. Secondly, neuronal death
may occur as a result of apoptosis or programmed cell death (PCD) as a result of DNA
fragmentation (Cotman & Su, 1996). Neuronal loss largely outnumbers NFT’s, thus
neuronal loss has a much greater correlation with cognitive impairment. The cognitive
impairment associated with AD is generally caused by neurodegeneration in the limbic
system, neocortical regions, and the basal forebrain as well as synaptic and dendritic
degeneration (Scheff, Price, Schmitt, & Mufson, 2005; Serrano-Pozo, Frosch, Masliah &
Hyman, 2011). Research indicates a significant correlation between the number of
synapses and cognitive function, with lower numbers of synapses resulting in poorer
cognitive performance (Scheff, Price, Schmitt, & Mufson, 2005). Synaptic loss is a
precursor to neuronal loss and is a main contributor to cortical atrophy. Synaptic loss
disrupts the connections both within and between neurons, which is why synaptic density
has the highest correlation with cognitive decline.
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Aside from cognitive decline, individuals with AD present with deficiencies in
numerous bodily functions. Cardiovascular disease (CVD) has been shown to correlate
highly among persons with non-genetic AD. Non-genetic AD includes persons who
present with AD pathology but lack the predisposing genetic traits commonly found in
persons with the disease (e.g., Apolopoprotein E gene). A high percentage of individuals
with AD present with cardiovascular conditions such as atherosclerosis, high blood
pressure, hypertension, and coronary artery disease (De La Torre, 2002; Stewart, 1998).
Epidemiological research suggests that CVD may directly contribute to AD pathology
and more specifically, CVD may actually have a direct impact on AD pathology (De La
Torre, 2002; Newman et al., 2005; Stewart, 1998). Conditions such as atherosclerosis
have been shown to reduce cerebral blood flow to the brain (known as cerebral perfusion)
resulting in impairment and white matter hyperintensity (De La Torre, 2002).
Medications that improve cognitive function such as cholinesterase inhibitors (ChEls),
also increase cerebral perfusion reinforcing the link between the cardiovascular system
and neurocognitive functioning (De La Torre, 2002).
Despite some of the distinct and unique differences in the symptomology of
vascular dementia (VaD) and AD, there is also overlap with both clinical and
pathological presentations. For example, individuals with VaD and AD both present with
white matter changes, cerebral hypoprefusion (reduced cerebral blood flow), and genetic
predispositions (De La Torre, 2002). The overlap in AD and VaD pathologies suggests
that both diseases are influenced by similar processes. In addition to CVD, another bodily
function which demonstrates decline as a result of AD pathology includes respiratory rate
(Hrouova et al., 2012). Respiratory rate is controlled by the autonomic nervous system,
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which is a subsystem of the peripheral nervous system. Autonomic nervous function is
influenced and regulated by the neurotransmitter acetylcholine (ACh; Wessler, et al.,
2007). Therefore, decreases in respiratory rate may be the direct result of changes in
cholinergic function and autonomic nervous function as a result of AD pathology. As
indicated in this research, AD pathology appears to extend beyond the neurodegenerative
symptoms commonly associated with the disease and cardiac autonomic function appears
to play an important role in the disease.
AD Risk Factors
A large number of demonstrable risk factors have been shown to increase the
etiology and likelihood of developing AD. Well-supported and correlated risk factors
include: genetic vulnerability, cardiovascular disease (CVD), aging, ethnicity, physical
inactivity, cognitive inactivity or low educational attainment, diabetes, midlife obesity,
smoking, mild cognitive impairment, and ethnic background (Alzheimer’s Association,
2013; Barnes & Yaffe, 2011; Kalaria et al., 2008).
Genetics. The role of genetics in AD is heterogeneous and complex. Those who
have a family member with AD are at greater risk for developing the disease
(Alzheimer’s Association, 2013). AD that occurs before the age of 60 to 65 years of age
is quite rare, and is referred to as autosomal dominant Alzheimer’s disease (ADAD) or
early-onset AD. Early-onset AD is caused by mutations of three primary genes, all of
which alter the production of amyloid-β (Aβ) peptide (Bertram & Tanzi, 2008). As
previously mentioned, the production of Aβ is generated from the amyloid precursor
protein (APP). The mutations associated with early-onset AD are located on the APP
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gene or in the genes that are responsible for encoding proteins; these are presenilin 1
(PSEN1) and presenilin 2 (PSEN2). The three primary genes involved in early-onset AD
are referred to as deterministic genes, and almost guarantee that anyone with these
specific gene mutations will develop the disease. Unlike early-onset AD, late-onset AD
appears to develop from a multitude of risk alleles across different genes. These risk
alleles are associated with the production, aggregation, and removal of Aβ peptide
(Bertram & Tanzi, 2008). The gene most consistently linked to late-onset AD, is the
Apolopoprotein E (apoE) gene (Blacker et al., 1997). The apoE gene contains four
chromosomes, the fourth chromosome (apoE-4) of which is overrepresented in persons
with late-onset AD. Although apoE-4 allele increases the risk of developing AD, only 2025% with inherent apoE-4 actually develop the disease suggesting that other factors are
contributing to the etiology of the disease (Alzheimer’s Association, 2013).
Cardiovascular Function. Research into the relationship between cardiovascular
disease (CVD), AD, and cognitive decline is well established (Barnes & Yaffe, 2011;
Newman et al., 2005; Stamper, 2006). Results from a cohort study of 4,971 older adults
indicated that mean scores were lower on a test of general cognitive ability (Mini Mental
State Examination) among individuals with a previous vascular event. Other factors that
correlate with lower general cognitive ability scores include the presence of plaques in
the carotid arteries and peripheral arterial atherosclerotic disease (PAD; Breteler, Claus,
Diederick, Grobbee, & Hofman, 1994; Stampfer, 2006). Furthermore, research has
indicated a higher prevalence of AD among those with clinical and subclinical coronary
artery disease, raised systolic blood pressure, high serum cholesterol in mid-life, and
hypertension (Barnes & Yaffe, 2011; Kivipelto et al., 2001; Newman, Ftizpatrick, &
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Lopez, 2005). Autopsy studies have demonstrated a close relationship between the
number of microvascular ischemic lesions as a result of cardiovascular incidents and
Alzheimer lesions, indicating a probable interaction between the two (Stampfer, 2006). In
corroboration with the above cardiovascular risk factors, Snowdon (2001) identified a
34% prevalence rate of stroke among 118 nuns diagnosed with AD. This study was
unique, because the nuns used in the study did not present with a history of negative
lifestyle behaviors (such as alcohol use, drug use, or poor diet) therefore reducing the
likelihood of confounding variables. Snowdon (2001) also demonstrated that older
women required an eight fold increase of NFT’s to produce the same dementia severity as
a person who has experienced a stroke, suggesting that dementia severity is mediated by
cardiovascular incidents. It is also well established that certain ethnic groups present with
a higher prevalence of both AD and CVD. For example, Latinos and African-Americans
present with higher prevalence rates of AD compared to Caucasians, which coincides
with a greater prevalence of CVD, metabolic syndromes (namely diabetes), high blood
pressure, and high cholesterol (Alzheimer’s Association, 2013). Therefore there is a
probable link between these two factors.
Aging. Increased age is one of the most highly correlated risk factors associated
with AD. The risk of developing AD doubles every five years after the age of 65 and
after the age of 85 the risk increases to nearly 50% (Alzheimer’s Association, 2013).
Exposure to deleterious conditions throughout life such as poverty, infectious diseases,
malnutrition, and prenatal stress, may compromise healthy aging (Kalaria et al., 2008).
Ethnicity. Research has indicated that HRV indices vary among different ethnic
populations (e.g., African-American’s compared to European American’s). In particular,
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African-American’s tend to generate higher levels of high frequency power and RMSSD
and lower levels of low frequency power as compared to European Americans (Wang,
Thayer, Treiber, & Snieder, 2005). This suggests that African-Americans have a
propensity towards greater parasympathetic modulation and greater sympathovagal
balance in comparison to European Americans. Therefore, it is important to consider
these factors when evaluating HRV among different ethnic groups.
Physical Inactivity. According to a meta-analysis of 16 prospective studies
exploring physical inactivity and AD prevalence, approximately 1.1 million AD cases are
potentially attributable to physical inactivity (Barnes & Yaffe, 2011). Individuals who
engage in physical activity at least twice a week have 60% lower odds of developing AD
and cognitive impairment compared to those who engage in frequent sedentary behavior
(Barnes & Yaffe, 2011; Rolland, Kan & Vellas, 2008; Rovio et al., 2005). The effects of
physical inactivity on cognitive decline are also more pronounced among individuals that
carry the apoE-4 gene, suggesting that physical activity may somehow modify the
development of apoE-4 gene mutations (Rovio et al., 2005). Reductions in cognitive
decline among persons who exercise regularly are likely to be related to the
cardiovascular benefits of physical activity. Physical activity mitigates conditions that
increase the risk of developing dementia such as hypertension, hypercholesterolemia,
diabetes mellitus, and obesity (Rovio et al., 2005).
Cognitive Inactivity & Low Educational Attainment. Both cognitive inactivity
and shorter years of education pose as risk factors for AD pathology (Barnes & Yaffe,
2011; Hall, Sujuan, Frederick & Hendrie, 2000). Individuals with higher levels of
education (more years in education) and higher occupational attainment show less
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clinical signs of memory loss when compared to those with lower educational and
occupational attainment (Attix & Welsh-Bohmer, 2006). However, research findings
suggest that persons with higher educational attainment are better able to find ways to
compensate for memory decline using compensatory strategies (also known as cognitive
reserve). Those with higher cognitive reserve tend to show a slower decline in memory
function at the early stage of the disease, but experience more rapid/stepwise progression
when global functions become impaired (Reed, et al., 2010; Scarmeas, Albert, Manly &
Stern, 2006).
Obesity. Longitudinal epidemiological meta-analyses demonstrate higher rates of
AD among persons with a history of obesity (Barnes & Yaffe, 2011; Profenno,
Porsteinsson, & Farone, 2010). In particular, high body mass index (BMI) is associated
with an increased risk of all-cause dementia. According to the National Heart, Lung, and
Blood Institute (2014), a normal BMI is considered to be between 18.5 (kg) and 24.9 (kg)
while a BMI of 30 (kg) or greater is considered overweight. It is thought that obesity may
exacerbate the causal mechanisms involved in the development of the disease via a
genetic interaction. Those with a higher BMI present with a greater prevalence of the fat
mass and obesity associated gene or the FTO polymorphism (Keller, Xu, Wang, Winbald,
Fratiglioni, & Graff, 2010). An interaction seems to exist between the FTO gene and the
apoE-4 gene, and those carrying the FTO gene appear to have a greater expression of the
apoE-4 gene resulting in a greater risk of AD. The effects of obesity have been shown to
coincide with the increased risk of developing CVD and metabolic syndromes such as
diabetes, both of which significantly increase AD risk (Profenno, Porsteinsson, & Farone,
2010; Sharma, 2003). Individuals who present with both diabetes and an apoE-4 allele,
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have approximately double the risk of developing the disease in comparison to those who
possess neither (Messier, 2003). Overall, obesity appears to be a risk factor for AD due to
its negative impact on the cardiovascular system.
Smoking. Smoking furthers the risk of developing AD particularly among those
who carry the apoE-4 gene (Barnes & Yaffe, 2011; Ott et al., 1998; Rusanen et al., 2010).
Smoking is a heavy detriment to the cardiovascular system, often resulting in a higher
risk of a myocardial infarct (MI), coronary artery disease (CAD), carotid wall thickening,
and internal carotid stenosis (Ambrose & Rajat, 2004; Tell et al., 1994).
Mild Cognitive Impairment. Mild cognitive impairment (MCI) is a prodromal
state of cognitive function that falls between the changes seen in healthy aging and
meeting criteria for dementia (Peterson, 2011; Kalaria et al., 2008). MCI is classified into
two subtypes; amnestic and non-amnestic mild cognitive impairment. Amnestic MCI
primarily affects memory function, and persons with amnestic MCI often present with
increasing forgetfulness but other functions are spared (e.g., executive functioning). The
capacities affected by non-amnestic MCI generally include executive and visuospatial
function with memory largely remaining intact. The prevalence of MCI among those
aged 65 years and older is approximately 10-20%. The rate in which those diagnosed
with MCI who eventually go on to develop AD is approximately 5-10% in community
samples and 10-15% in clinical samples (Peterson, 2011). Individuals who present with
the apoE-4 gene, a hippocampal volume below the 25th percentile, and elevated levels of
cerebral spinal fluid (CSF) tau protein, are at greater risk of developing AD after being
diagnosed with MCI.
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Overall, there are numerous factors that exacerbate the risk of developing AD.
Although individual factors pose an increased risk, combinations of risk factors such as
the apoE-4 genotype and high BMI seem to drastically increase the risk of developing the
disease above and beyond individual factors. Two of the greatest risk factors for AD
include a genetic predisposition and CVD. These risk factors are then mediated by
negative lifestyle behaviors such as physical inactivity, and alcohol and tobacco use. The
relationship between CVD and negative lifestyle behaviors may also be bi-directional,
with negative lifestyle behaviors increasing the likelihood of developing CVD. Therefore,
it is the interaction of multiple risk factors that may increase the overall risk of a person
developing AD.
Cholinergic Function and Cardiac Autonomic Function
In addition to the positive and negative symptoms present in the AD brain,
changes in the neurotransmitter system also occur in persons with the disease. The
neurotransmitter acetylcholine (ACh) plays a primary role in neurocognitive function
(mainly learning and memory) and cardiac autonomic function. Cholinergic resources
become increasingly deficient in the AD brain resulting in neurocognitive impairment
and cardiac autonomic dysfunction (Bartus, 1999; De Vilhena & Fernando, 2009;
Feldman, 2001; Schliebs & Arendt, 2006). Decreases in choline acetyl transferase
(ChAT), a biochemical marker for cholinergic neurons, are found in the brain of AD
patients (Muir, 1996). Reductions in levels of ACh are caused by the loss of presynaptic
neuronal structures (e.g., ChAT) in the basal forebrain. A landmark study by Perry,
Tomlinson, Blessed, Bergman, & Gibson et al (1978) demonstrated a strong correlation
between cholinergic neuronal loss identified via autopsy and decreased mental state
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examination scores (Muir, 1996). These findings along with others were significant in the
development of the “cholinergic hypothesis”, which theorized a link between cholinergic
resource depletion in the central nervous system and decreased cognitive function
(Bartus, 1999). The cholinergic hypothesis in comparison to a number of other theories
pertaining to the neurodegenerative pattern in AD, has produced strong evidence of
efficacy in well controlled, multicenter trials (Muir, 1996). Early studies showed support
for the theory when the symptoms of memory loss seen in the AD presentation were
replicated by blocking cholinergic receptors in young adults (Schliebs & Arendt, 2006).
More recent studies have provided supporting evidence for the hypothesis using in-vivo
measurements of cholinergic receptor expression via positron emission tomography
(PET) technology (Schliebs & Arendt, 2006). Additionally, researchers Toledo &
Junqueira (2009) explored correlations between MMSE scores from AD participants and
HRV indices. Results from this study indicated that cognitive deficiency was correlated
with lower cardiac parasympathetic modulation and a trend for higher cardiac
sympathetic modulation.
Cholinergic neurons can be subdivided into two categories: projection neurons
and interneurons. Projection neurons are primarily concentrated in the forebrain and
upper brain stem, whereas interneurons are located in the caudate-putamen (cerebral
cortex),

nucleus

accumbens

(basal

forebrain),

hippocampus,

cerebral

cortex,

hypothalamus, and spinal cord (Schliebs & Arendt, 2006). Most importantly, cholinergic
projection neurons also comprise of motor neurons in the spinal cord and cholinergic
neurons in the sympathetic (SNS) and parasympathetic nervous system (PNS).
Cholinergic function is involved in controlling cerebral blood flow, cortical activity, the
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sleep-wake cycle, and modulating cognitive function (Schliebs & Arendt, 2006).
Cholinergic function is a primary regulatory neurotransmitter of the autonomic nervous
system (ANS). The autonomic nervous system regulates both the sympathetic and
parasympathetic nervous system, and is involved in cardiac regulation as well as
respiration (Task Force on Heart Rate Variability, 1996).
For more than 40 years, AD has been classified as a genetic neurodegenerative
disorder but epidemiological studies indicate that AD may also be non-genetic and
initiated by vascular factors that precede the neurodegenerative process (De La Torre,
2002). Cardiac autonomic dysfunction is prevalent among individuals with AD, and this
generally reflects an increase in sympathetic activity and a decrease in parasympathetic
activity (or parasympathetic depression; Toledo & Junqueira, 2009). This could be a
direct result of cholinergic dysfunction, and it is well established that persons with AD
generally present with depleted cholinergic resources in tandem with autonomic
dysfunction indicating a probable link between the two. Examples of autonomic
dysfunction among those with AD can include increased cardiovascular mortality, higher
risk of arrhythmias, sudden death, and other cardiac events (Allan et al., 2007; Kleiger,
Miller, Bigger, & Moss, 1986). A relationship between higher cognitive function and
autonomic function has been demonstrated which could be mediated by cholinergic
function (Critchley, 2005; Hugdahl, 1996; Royall et al., 2006). Therefore, it is possible
that cardiac autonomic dysfunction may represent a decrease in cholinergic resources as
well as increased cardiovascular risk.
In contrast to the evidence indicating a direct and causal link between cardiac
autonomic dysfunction and AD (or vice-versa), other studies have indicated a parallel
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process whereby AD and cardiac autonomic dysfunction co-occur. For example, the
existence of cardiac autonomic dysfunction (e.g., cerebrovascular disease) may lead to
deep white matter infarction and subsequent white matter disease (WMD; Andin,
Passant, Gustafson, & Englund, 2006). White matter disease correlates highly with AD
and cerebral amyloid angiopathy (CAA). CAA is the build-up of amyloid plaques within
the walls of brain arteries, and these plaques are similar to the Aβ plaques found in the
AD brain. As vascular complications progress (e.g., atherosclerosis and CAA), the
severity of AD tends to progress in a similar fashion (Andin, Passant, Gustafson, &
Englund, 2006; De La Torre, 2002).
In corroboration with the evidence surrounding a parallel process, cardiovascular
conditions have been shown to cause reduced cerebral perfusion (cerebral blood flow) or
hypoperfusion as well as cognitive impairment (Toledo Ferraz Alves, Ferreira,
Wajngarten, & Busatto, 2010). This hypoperfusion pushes oxidative stress towards the
brain resulting in cognitive decline (De La Torre, 2002). Hypoperfusion is likely a
precursor to AD pathology but may also mediate AD symptomology. It is also wellknown that Aβ and NFT’s have been found in the brains of healthy older adults who
show no signs of AD (De La Torre, 2002). As mentioned previously, Snowdon (2001)
demonstrated that older women required an eight fold increase of NFT’s to produce the
same dementia severity as a person who has experienced a stroke, suggesting that
dementia severity is mediated by cardiovascular health. This could indicate that a parallel
process involving both cardiovascular and neurocognitive systems is necessary to induce
AD pathology.
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Donepezil
The medication Donepezil hydrochloride (Aricept®) is a popular ChEls used to
treat cognitive impairment among persons with AD. Donepezil is a highly selective
ChEls designed to prevent and slow the progression of cholinergic deficiency which
greatly impacts neurocognitive function (Feldman et al., 2001; Bartus, 1999). ChEls
operate by blocking the acetylcholine esterase (AChE) and butylcholinesterase (BuChE)
enzymes which typically hydrolyze acetylcholine (Rogers, 1998). The recommended
dose for persons taking Donepezil is 5mg over a period of four to six weeks which is then
titrated to the therapeutic dose of 10mg if the medication is well tolerated (Feldman et al.,
2001; Mohs et al., 2001). Results from a number of placebo-controlled studies looking at
the effects of Donepezil on cognitive function have indicated significant reductions in the
rate of cognitive decline (neurodegeneration) and mild cognitive gains in persons with
mild to moderate AD who are taking the medication (Mohs et al., 2001; Rogers et al.,
1998; Feldman et al., 2001). This reduction in cognitive decline and improvement in
cognitive functioning during Donepezil treatment appears to be evident after six weeks of
taking the medication (Mohs et al., 2001; Rogers, 1998) but greater gains can be seen at
six months (Mohs et al., 2001). Additional findings suggest that Donepezil may also help
reduce cognitive decline among persons with more progressive and severe stages of the
disease (Feldman, 2001).
Although Donepezil may slow the rate of cognitive decline, the medication and
other ChEls have been shown to cause uncommon side effects such as dizziness and
syncope, bradycardia (abnormally slowed heart rate), atrial arrhythmias, myocardial
infarction, angina, seizures, atrioventricular block, and orthostatic hypotension (Bordier,
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2006; Calvo-Romero & Ramos-Salado, 1999; Newby, Kenny, & McKeith, 2006;
Rowland, Rigby, Harper, & Rowland, 2007). These adverse effects are however mostly
seen in cases where the amount of Donepezil metabolized has greatly exceeded the
therapeutic dose, but some have reported mild side-effects from the recommended dose
(Bordier et al., 2005). The prevalence of bradycardia as a result of taking Donepezil is
rare with the base rate being around 1% (Bordier et al., 2005; Rowland, Rigby, Harper, &
Rowland, 2007). It is important to mention that bradycardia is fairly common among the
general population (all ages), with approximately 15% of males and 2% of females
meeting criteria for clinically defined bradycardia (Ostchega, Porter, Hughes, & Dillon,
2011). Thus, the percentage of individuals developing bradycardia as a result of taking
Donepezil is quite low in comparison to the general base rate. The frequency of adverse
events such as dizziness and syncope are more common, and are reported in around 110% of persons taking the medication (Rowland, Rigby, Harper, & Rowland, 2007).
Atrioventricular block is exceptionally rare, and occurs in 0.001-0.1% of those taking the
medication.. It is hypothesized that side-effects such as bradycardia and arrhythmia are
triggered by increased acetylcholine production or increased vagal neurotransmission
which acts to slow heart rate. However, Donepezil has also been shown to improve
cardiac autonomic dysfunction by increasing heart rate variability (HRV) among persons
with AD as well as animal subjects (Giubilei et al., 1998; Umegaki & Khookhor, 2013).
Limitations to these studies include measuring changes in HRV at a single (and varied)
time frame (12 weeks ± 4 weeks), using a now discontinued ChEI, measuring changes in
HRV over a short time frame (2 weeks), the absence of normalized units when
identifying changes in HRV over time (Masuda & Kawamura, 2003; Umegaki &

29

Khookhor, 2013), using animal subjects (rats), and the lack of a healthy control group
(Da Costa Dias et al., 2013; Giubilei et al., 1998; Umegaki & Khookhor, 2013).
Previous research has also explored the medium term effects of cholinesterase
inhibitors on cardiac health. For example, researchers Nordstrom et al (2013) studied the
prevalence of myocardial infarcts (MI) and rate of death among individuals with AD who
were taking a cholinesterase inhibitor (N= 7,073) over a period of five years. Results
from the study found that participants who used ChEls had a 34% lower risk of
experiencing an MI. Cholinesterase inhibitor use was also associated with a lower risk of
death. Therefore, Donepezil may present with cardio-protective properties in addition to
improving neurocognitive function. These positive side-effects of the medication
Donepezil are likely the result of changes in cardiac autonomic function as a result of
increased ACh production.
Heart Rate Variability (HRV)
Over the past 25 years, there has been an increased recognition in the relationship
between the autonomic nervous system (ANS) and cardiovascular mortality (Task Force
on Heart Rate Variability, 1996). Following the recognition of ANS markers and the
consequences of autonomic dysfunction, interest in obtaining heart rate variability (HRV)
measures via electrocardiogram (ECG) have grown significantly (Balocchi et al., 2006).
Epidemiological and clinical data using ECG technology indicate autonomic and
neuroanatomic dysfunction in persons with AD, and more specifically parasympathetic
depression (Bartus, 1999; Giubilei et al., 1998; Toledo & Junqueira, 2008, 2009; Zullii et
al., 2005). Heart rate and heart rhythm are primarily controlled by the autonomic nervous
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system (ANS), which comprises of two distinct subsystems; the sympathetic nervous
system (SNS) and the parasympathetic nervous system (PNS). The SNS and PNS work in
complementary and opposing ways. The PNS influences heart rate by the release of ACh
neurotransmission via the vagus nerve. The release of ACh results in diastolic
depolarization which causes heart rate activity to slow (Task Force on Heart Rate
Variability, 1996). Reductions in PNS activity is often referred to as vagal withdrawal,
and is indicative of impaired autonomic function. Neurotransmitters including the release
of epinephrine and norepinephrine, activate adrenergic (adrenaline) receptors causing an
increased SNS response and slowed diastolic depolarization.
Heart rate variability is monitored using ECG technology which provides an
algorithm of SNS and PNS activity. Assessment of SNS and PNS activity can be
obtained via spectral analysis of HRV which provides both low frequency (LF) and high
frequency (HF) cardiovascular output. Increased vagal afferent excitation results in vagal
efferent activity (PNS) which (in turn) inhibits the sympathetic nervous response.
Efferent vagal activity is of high interest here, because it can be measured by HF HRV
output from an electrocardiogram (ECG) thus providing a quantitative measure of PNS
activity. The simplest measurement of HRV is the time domain method, which utilizes
the individual’s heart rate at a certain point in time and the intervals between successive
normal complexes (also known as RR interval variability; Task Force on Heart Rate
Variability, 1996). The time domain method can be used to capture both short-term (e.g.,
5-7 minutes) or long-term recordings (e.g., 24 hour period). Due to the nature of this
study, short-term recordings will be obtained over a period of six minutes in two different
positions (supine and standing). Short-term recordings (5 minute intervals) have been
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used in previous studies to accurately capture HRV data in persons with AD (Allan et al.,
2006; Giubilei et al., 1998; Siepmann et al., 2006; Toledo & Junqueira, 2008). The most
commonly used time-domain measures include the mean squared differences of
successive R-R intervals (RMSSD). This is used as a measurement to estimate the high
frequency variations in heart rate.
Using short-term recordings, the following spectral components can be derived
from the HRV algorithm; low frequency (LF), high frequency (HF) and LF/HF ratio. The
proportional variations of LF and HF output are represented by the LF/HF ratio. The
spectral components are available in both absolute values (ms2) or normalized units (n.u.)
and represent changes in autonomic heart function. The advantage of using normalized
units surrounds the emphasis on the controlled and balanced behavior of the sympathetic
and parasympathetic nervous system (Task Force on Heart Rate Variability, 1996). Using
normalized units (n.u.) emphasizes changes in sympathetic and parasympathetic
regulation by minimizing the effects of Very Low Frequency power. The Task Force on
Heart Rate Variability (1996) state that power in normalized units (n.u.) should always be
reported with absolute values of LF and HF Power in order to describe in total the
distribution of power in the spectral components. Normalized units are also advantageous
for tracking changes over time (e.g., when using a repeated measures design) and are
similar to a standard score. In addition to this, the normalization process expresses the
quantities more easily by using percentage values (0%-100%). Normalization also
reduces most of the large within and across-subject variability in the total raw HRV
spectral power as well (Burr, 2007).
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With regards to standardized HRV data using normalized units, a meta-analysis of
44 publications exploring short-term HRV among healthy adults (≥ 18 years) suggests
that mean normal values of low frequency power (expressed in normalized units) should
be approximately 52% (SD= 10), while mean normal values of high frequency power
(expressed in normalized units) should be approximately 40% (SD= 10; Nunan,
Sandercock, & Brodie, 2010). Additionally, mean normal values of RMSSD should be
approximately 42 (ms; SD= 15) while the mean normal value of the LF/HF Ratio should
be approximately 2.8 (SD= 2.6; Nunan, Sandercock, & Brodie, 2010). It is important to
mention that the mean values generated from this study were based on HRV data
obtained in a range of positions (e.g., supine, standing, resting etc.) and from individuals
of varying ages (≥18).
Previous studies have explored frequency domain analysis using LF, HF, and
LF/HF ratio indices to determine cardiac autonomic change among those with AD versus
healthy controls (Allan et al., 2007; Da Costa Dias, et al., 2013; Giubilei et al., 1998;
Masuda & Kawamura, 2003; Toledo & Junqueira, 2009). Using a cross-sectional design,
researchers Toledo & Junqueira (2008) studied cardiac autonomic function and cognitive
function in 22 participants with probable AD (Mean age = 79.6) and compared them to
24 healthy participants (Mean age= 68.6). Cardiac autonomic function was measured
during five minute HRV intervals and frequency domain indexes in both supine and
standing positions. The HRV analysis was performed according to the methodological
standards recommended by the Task Force on Heart Rate Variability (1996). Each
individual completed a five minute series of R-R intervals in both supine and standing
positions using digital ECG technology and compatible software. Both time-domain and
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frequency-domain analyses were conducted (Toledo & Junqueira, 2008). Cardiac
sympathetic and parasympathetic modulation was measured using a time-domain
analysis, a mean R-R interval series and two variability indices. This included the
standard deviation of intervals (SDNN) and the coefficient of variation (SDNN/mean).
Two separate indices were also used and included the percentage of successive adjacent
R-R intervals greater than 50 ms (pNN50%), and the square root of the mean successive
differences between adjacent R-R intervals (RMSSD; Task Force on Heart Rate
Variability, 1996). These reflect the rapid beat-to-beat shifts in intervals that are derived
from the parasympathetic modulation associated with respiration (Toledo & Junqueira,
2008).
Frequency domain analyses were also conducted by the authors, which provided a
functional measure of HRV frequency distribution. These frequencies included very low
frequency (0–0.04 Hz), low frequency (0.04–0.15 Hz), and high frequency (0.15–0.50
Hz) spectral bands. The frequency domain measures include total power spectral area,
which demonstrates the level of the overall autonomic modulation. Low frequency bands
are a measure of SNS activity while high frequency bands are an indication of PNS
activity (Task Force on Heart Rate Variability, 1996). The ratio of the low to high
frequency indices (LF/HF ratio) provides an estimative of the sympathovagal balance. If
the LF/HF ratio is less than 1, then this indicates a dominance of parasympathetic
modulation whereas if the ratio is greater than 1, this is indicative of sympathetic
dominance (Toledo & Junqueira, 2008). The mean and frequency domain indices in each
group were compared using Student t-tests. Multiple logistic regression analyses were
conducted to verify if the HRV indices were affected by independent confounding
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variables (e.g., caffeine use, blood pressure, and alcohol use). Logistic regression
analyses revealed changes in sympathovagal balance, which was altered towards
parasympathetic depression and sympathetic exacerbation in both the supine and standing
posture among persons with AD (Toledo & Junqueira, 2008).
Supporting evidence for reductions in HRV were identified in similar studies by
Zulli et al (2008) and Allan et al (2007). Zulli et al (2008) compared HRV markers of 33
participants with AD and 29 participants with MCI to healthy controls using 24-hour
ECG monitoring. The researchers also monitored blood pressure changes over a 24-hour
period, and controlled for various lifestyle behaviors including smoking habits and
hypertension. High and low blood pressure have been linked to changes in cardiac
autonomic function, which is why this factor was a potential confound (Acharya, et al.,
2006; Pavithran, Prakash, Dutta, & Madanmohan, 2010). Persons with a history of heart
failure, coronary artery disease, diabetes mellitus, or severe clinical conditions (e.g.,
cerebrovascular disorders) were excluded from the study. Student t-tests were conducted
to detect changes in continuous variables, and categorical variables were analyzed using a
chi-square analysis. The authors then used a Pearson linear correlation analysis to
evaluate the correlation between HRV and cognitive impairment. Results indicated that
HRV time and frequency domain parameters were lower in patients with AD in
comparison to patients with MCI and healthy controls (Zulli et al., 2008). More
specifically, the AD group showed much lower high frequency output compared to
healthy controls. Allan et al (2007) compared HRV among persons with AD, VaD, and
Lewy Body Dementia (LBD) using ECG technology. Results further indicated decreased
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PNS activity among individuals with all types of dementia suggesting that decreased
autonomic dysfunction is not unique to dementia of the AD type.
Currently, there are only a few studies exploring the cardio-protective benefits of
ChEl treatment among individuals diagnosed with AD. One of these studies was
conducted by researchers Giubilei et al (1998). In this study, authors Giubilei et al (1998)
explored cardiac autonomic function in persons with probable AD (n= 12) versus healthy
controls (n= 12). The AD group were receiving ChEl treatment for one month using a
now discontinued medication named eptastigmine. Before the participants received
eptastigmine, a recording of the HRV was performed during a head-up tilt test. This was
then repeated on the last day of treatment. The same frequency bands used in the Toledo
& Junqueira (2008) study were used in this study (HF, LF, and LF/HF ratio). Results
indicated that before treatment, HF Power (parasympathetic function) was lower in AD
participants compared to healthy controls while in the resting position. Following one
month of ChEl treatment, AD participants showed a similar magnitude of HF Power in
the resting position compared to healthy controls. Additionally, AD participants showed
similar patterns of HRV output following ChEl treatment when placed in the tilting
position compared to healthy controls. Overall, both groups showed similar increases in
the magnitude of LF Power and decreased HF Power when placed in the tilting position.
The authors concluded that cardiac autonomic dysfunction may be present in persons
with AD as a result of a cholinergic deficit in the peripheral autonomic nervous system.
However, this cardiac autonomic dysfunction can be normalized by ChEl treatment
(Giubilei et al.,1998). A major limitation to this study includes the use of a now
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discontinued ChEls and the short time frame in which pre/post measures were obtained
(one month).
Another study conducted by Masuda & Kawamura (2003) explored the effects of
the more modern and widely used cholinesterase inhibitor Donepezil hydrochloride
(Aricept®). The authors examined the effects of Donepezil on autonomic nervous
activity among 17 participants with a diagnosis of probable AD. The severity of AD was
controlled for in the analysis by quantifying dementia severity using a dementia screening
tool. Using 24-hour ECG technology, Masuda & Kawamura (2003) obtained HRV before
the participants began taking Donepezil and six weeks after the participants started
Donepezil. Participants were however initially administered a 3mg dose of Donepezil in
the morning for 2 weeks as a running-in period and after these 2 weeks, the dosage was
increased to 5mg per day where it remained. HRV was measured using frequency domain
analyses over a 24-hour period. Results indicated that low frequency and high frequency
components were significantly reduced with treatment and ultralow and very low
frequency components were not affected. The reduction in the high frequency
(cholinergic) component was also greater than the reduction in the low frequency
component, indicating a greater decrease in parasympathetic (cholinergic) activity in
comparison to sympathetic activity over the period of six weeks. Results from this study
indicate that Donepezil reduced parasympathetic activity and cholinergic function among
those taking Donepezil, which contradicts the findings from Giubilei et al (1998) and
Umegaki & Khookhor (2013).
Similar findings to the Masuda & Kawamura (2003) study were also obtained by
Siepmann et al (2006) and McLaren et al (2003). Siepmann et al (2006) explored the
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effects of Donepezil treatment on RMSSD among individuals diagnosed with AD while
in the resting position. RMSSD was captured using HRV technology at a single time
frame. The duration in which ChEl treatment was administered was not specified. The
authors also used an AD control group who were not being treated with Donepezil.
Results indicated a lower magnitude of RMSSD (parasympathetic nervous activity)
among the AD group during Donepezil treatment versus the AD (non-ChEl treatment)
control group. Major limitations to this study include the use of a single time frame to
capture HRV, the absence of normalized units, as well as the unspecified length of time
in which individuals with AD were taking the medication Donepezil. Additionally,
researchers McLaren et al (2003) explored the effects of Donepezil on HRV among
individuals diagnosed with AD and Lewy Body Dementia before and after ChEl
treatment. HRV was obtained through the use of a five minute HRV analysis. Results
indicated that HRV was significantly reduced following treatment with Donepezil as
indicated by reductions in high frequency power. Limitations to this study include the use
of a single time frame, absence of a control group, and absence of normalized units. The
researchers of both studies did not account for various confounding factors (e.g., physical
activity, caffeine use, gender) which have been shown to influence HRV.
A more recent study conducted by researchers Umegaki & Khookhor (2013),
explored the effects of Donepezil (3mg) on HRV using animal (rats) subjects. The
authors administered Donepezil to 32 rats and monitored their low frequency (LF), high
frequency (HF) and the LF/HF Ratio indices over a period of two weeks. The rats HRV
was obtained on the day the initial dose was ingested and at one and two weeks after the
initial dose was ingested. On day one, authors found an increase in sympathetic nervous
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activity as evidenced by LF dominance (LF/HF Ratio). However, at weeks one and two,
the magnitude of the LF output had decreased significantly and HF dominance was
apparent. The authors concluded that initially ChEl treatment induced sympathetic
nervous

activation

acutely,

but

longer-term

ingestion

(two

weeks)

induced

parasympathetic activation. Additionally, another recent study exploring the effects of
ChEl treatment on HRV and blood pressure, identified improvements in cardiac
autonomic balance and diastolic and systolic blood pressure following ChEl treatment
(Da Costa Dias, et al., 2013). In older adults, increasing blood pressure produces cardiac
slowing as a result of reductions in baroreceptor reflex sensitivity (Simpson & Wicks,
1988). The baroreceptor reflex is a strong reflex of the brainstem and baroreceptors are
located in the auricles of the heart and vena cavaeis (Berntson, 1997). The baroreceptor
reflex is involved in maintaining blood pressure and homeostasis. More specifically, if
blood pressure decreases the baroreceptor reflexes act to help restore blood pressure by
increasing heart rate. Baroreceptor reflexes exert powerful inhibitory influences on
sympathetic outflow and also stimulate vagal (ANS) activity (Berntson, 1997). As such,
older adults have the tendency to demonstrate poorer HRV with age but disease
pathology (e.g., dementia) causes larger decreases in HRV (Toledo & Junqueira, 2008).
The study by Da Costa Dias et al (2013) may suggest that decreases in high blood
pressure as a result of improved baroreceptor reflex sensitivity may in turn, improve heart
rate variability. Previous research has also indicated a strong relation between high blood
pressure and greater LF Power (sympathetic exacerbation) among hypertensive
participants versus healthy controls (Piccirillo, Munizzi, Fimognari, & Marigliano.,
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1996). Therefore, LF Power is thought to reflect baroreceptor-mediated regulation of
blood pressure (Bernston, et al., 1997; Friedman & Thayer, 1998).
Respiratory Sinus Arrhythmia (RSA)
In order to improve the accuracy of measuring parasympathetic activity via high
frequency HRV, respiration count is often incorporated into the HRV algorithm. This
measure is known as the respiratory sinus arrhythmia or RSA (Grossman & Taylor,
2006). The respiratory sinus arrhythmia is attributed to parasympathetic activity, and is
frequently utilized as an index of cardiac vagal tone (Grossman & Taylor, 2006). Cardiac
vagal tone is a process by which the vagus nerve controls and regulates the
parasympathetic nervous system and is responsible for homeostatic regulation. Heart rate
has been shown to synchronize with respiratory rhythm, and the R-R interval on an ECG
is shortened during inspiration and prolonged during expiration (Yasuma & Hayano,
2004). Therefore, obtaining respiratory parameters can be advantageous in providing a
more accurate measure of parasympathetic activity.
HRV Positioning
Research has demonstrated that HRV, diastolic and systolic blood pressure (BP),
high and low frequency band power of HRV all show significant changes when
positioning is altered from a supine to a standing posture (Acharya, et al., 2006;
American Heart Association, 1996; Aysin & Aysin, 2007). The orthostatic challenge
(supine to standing) is also one of the most common tests to detect cardiac autonomic
dysfunction (Aysin & Aysin, 2007). Physical activity has also been shown to cause
oscillations in blood pressure creating interference or “noise” with HRV measures
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(Gianfrance, Saul, Di Rienzo, & Mancia, 1994). Obtaining HRV readings from a still
resting position to a standing position will help identify any significant changes in SNS
and PNS activity. Toledo & Jaunqueira (2008) demonstrated large differences in high
frequency (HF) bands among persons in both supine (M= 28.0 ms2) and standing (M=
13.8 ms2) positions, which is consistent with previous research (Fagard, 2001). The heart
rate response to standing evaluates the cardiovascular response initiated by a change from
horizontal to a vertical position. The typical heart rate response to standing (increased
sympathetic activity) is largely mitigated by parasympathetic activity (Risk, Broadbridge,
& Cohen, 2001). In healthy individuals, there is a characteristic and rapid response to
standing which is followed by a relaxation bradycardia (Risk, Broadbridge, & Cohen,
2001). Research has shown that shifts in positioning (e.g., a head tilt or sit to stand)
among persons with AD and healthy older adults can alter HRV (Toledo & Junqueira,
2008). The present study will use both supine and standing positions to measure HRV.
Using a still resting position will also decrease the likelihood of additional frequency
interference (Gianfrance, Saul, Di Rienzo, & Mancia, 1994). It is recommended that the
participant should be in a resting position prior to commencing the standing
measurement. So far, the results of the few studies examining cardiac autonomic function
in AD present with varying results in frequency-domains. This is likely the result of
varying methods of measuring heart rate variability such as using a stand versus a supine
position or a 24-hour ECG (Giubilei et al., 1998; Masuda & Kawamura, 2003; Siepmann
et al., 2006; Toledo & Junqueira, 2008).
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HRV Confounds
When assessing HRV in the present study, it will be important to identify factors
that may influence cardiac autonomic function as these factors could undermine the
validity of the HRV analysis. It is well known that persons who present with severe
coronary artery disease, congestive heart failure, atherosclerosis, high blood pressure, or
stroke present with decreased heart rate variability (Kleiger, Miller, Bigger, & Moss,
1986; Kwon et al., 2008; Naver, Bloomstrand, & Wallin, 1996). More specifically,
measures of high frequency HRV appear to be significantly lower among persons with
cardiovascular disease indicating decreased parasympathetic nervous response (or vagal
withdrawal; Evrengul et al., 2006). Therefore, it will be important to exclude individuals
with severe cardiac conditions such as a history of stroke from the study, and control for
more mild cardiac conditions (e.g., high blood pressure) in the analyses.
Frequent exercise (two to three times per week) has also been shown to increase
heart rate variability as demonstrated by increases in high frequency HRV among young
and older adults (Sandercock, Bromley, & Brodie, 2005; Schuit et al., 1999). Therefore, it
will be necessary to document the amount of hourly exercise each participant engages in
per week as this could potentially inflate their levels of high frequency HRV. In addition
to this, body mass index, long-term smoking behaviors, and moderate and long-term
alcohol consumption have also been shown to decrease HRV and decrease
parasympathetic nervous response as measured by high frequency HRV (Harte &
Meston, 2013; Hayano et al., 1990; Koskinen, Virolainen, & Kupari, 1994; Molifino et
al., 2009). Individuals with alcohol dependence (based on DSM-5 criteria) will not be
eligible for the study as this can cause long-term vagal neuropathy (Malpas, Whiteside, &
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Maling, 1991). Older age is also associated with a global reduction in HRV and research
has indicated that gender may impact HRV as well (Fagard, 2001; Stein, Kleiger, &
Rottman 1997; Umetani, Singer, & McCraty, 1998). Interestingly, the level of decreased
HRV as a result of aging appears to be more pronounced in males in comparison to
females (Acharya, et al., 2006; Stein, Kleiger, & Rottman 1997; Umetani, Singer, &
McCraty, 1998). As a result of this, AD participants in the current study will be matched
with a healthy control based on age and gender.
The influence of medication should also be considered when interpreting HRV as
certain classes of medications can cause changes HRV. For example, beta-blockers that
are used to reduce hypertension and high blood pressure have been shown to improve
PNS activity and decrease SNS activity (Acharya, et al., 2006). Other medications such
as selective serotonin reuptake inhibitors (SSRI’s) and benzodiazepines can cause
adverse changes in blood pressure resulting in orthostatic hypotension (Tinetti & Kumar,
2010). These medications may interfere with HRV accuracy due to the resultant changes
in blood pressure. Therefore, medications will be controlled for in the analysis. Lastly,
acute caffeine ingestion has been shown to cause increased blood pressure, increased
SNS activity, and decreased HRV (Sondermeijer, Van Marle, Kamen, & Krum, 2002).
Therefore, participants will be required to refrain from caffeine ingestion 12 hours prior
to completing the ECG as this may interfere with the HRV reading.
Alzheimer’s Disease and Heart Rate Variability
To date, there are no studies exploring changes in autonomic function among
those diagnosed with AD who are taking Donepezil compared to an age and gender
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matched healthy control group over a period of six months using supine and standing
positions. This study will obtain time and frequency-domain HRV data using both supine
and standing positions at three separate time frames (session 1 [baseline]; session 2 [3
months]; and session 3 [6 months]). Special attention will be paid to the low and high
frequency indices as well as the LF/HF modulation ratio and the square root of the mean
successive differences between adjacent R-R intervals (RMSSD). Data pertaining to the
covariates described in the HRV confounds section will be obtained each session and
controlled for in the analyses.
The results of the few studies examining cardiac autonomic function in AD are
conflicting, which is likely due to the use of varying methods of measuring heart rate
variability (e.g., standing vs. supine vs. tilting positions vs. 24-hour). Limitations in the
methodology of previous studies include the lack of a healthy control group, the use of a
single time frame (cross sectional design) for data collection, the short period of time in
which participants were taking Donepezil, the absence of controlling for multiple
covariates, the failure to report HRV data in normalized (standardized) units (n.u.), the
absence of a respiration count and a respiratory sinus arrhythmia (RSA) measure, the use
of animal subjects, and the use of a single position to capture HRV (Allan et al., 2005; Da
Costa Dias Dias, et al., 2013; Giubilei et al., 1998; Masuda & Kawamura, 2003;
McLaren, et al., 2003; Siepmann, et al., 2006; Umegaki & Khookhor, 2013; Zullii et al.,
2005). Despite the methodological issues with these studies, the majority of the
researchers have indicated the presence of parasympathetic depression and sympathetic
exacerbation in persons with AD.
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In summary, HRV measures can be used to assess cardiac autonomic function,
and in some studies, ChEls have been shown to improve cardiac autonomic function in
persons with AD and animal subjects (Da Costa et al., 2013; Giubilei et al., 1998;
Nordstrom et al., 2013; Umegaki & Khookhor, 2013). The present study will address
some of the methodological limitations present in previous research. Firstly, participants
taking the medication Donepezil will be matched with a healthy control of the same age
(± 3 years) and gender, as both age and gender have been shown to influence HRV
(Stein, Kleiger, & Rottman 1997; Umetani, Singer, & McCraty, 1998). Secondly, the
participants in the current study will be taking Donepezil for six months and data will be
obtained at three different time points (baseline, three months, and six months). Few
studies (including Giubilei et al., 1998; Masuda & Kawamura, 2003; McLaren, et al.,
2003; Siepmann et al., 2006; Umegaki & Khookhor, 2013) have examined the
cardiovascular benefits of the medication after six weeks. Thirdly, the present study will
control for the following confounds as previous research has indicated that these factors
can interfere with HRV measures: age, gender, body mass index (BMI), blood pressure
(hypertension), medications (blood pressure, allergy, anxiolytic or antidepressant), length
of time on Donepezil, alcohol use, caffeine use, and physical activity (Harte & Meston,
2013; Hayano et al., 1990; Koskinen, Virolainen, & Kupari, 1994; Molifino et al., 2009;
Sandercock, Bromley, & Brodie, 2005; Sondermeijer, Van Marle, Kamen, & Krum,
2002; Stein, Kleiger, & Rottman 1997; Umetani, Singer, & McCraty, 1998). Participants
will not be eligible for the study if they are taking certain medications that may interfere
with HRV measures (e.g., anti-depressants), have a recent history of a cardiovascular
event (e.g., stroke), a recent history of a severe medical condition (e.g., cancer), or suffer
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from a severe psychological disorder (e.g., bi-polar disorder or schizophrenia). Fourthly,
the results will be reported in normalized units (n.u.) to emphasize the controlled and
balanced behavior of the sympathetic and parasympathetic nervous system (Task Force
on Heart Rate Variability, 1996). The normalization process will also provide more
meaningful quantities by using percentage values (0%-100%).
Fifthly, respiration count will be obtained as heart rate has been shown to
synchronize with respiratory rhythm. Capturing respiration and adding this to the HRV
algorithm will also serve to improve the accuracy of parasympathetic data via a measure
of respiratory sinus arrhythmia (Grossman & Taylor, 2006). This is an important indices
because heart rate increases during inhalation and decreases during exhalation.
Respiratory linked variations in heart rate also usually occur in the high frequency (HF)
range (Lehrer, Vaschillo, and Vaschillo, 2000). Finally, the present study will obtain
HRV measures in both supine and standing positions as previous studies (Da Costa et al.,
2013; Giubilei et al., 1998; Masuda & Kawamura, 2003; Siepmann et al., 2006; Toledo &
Junqueira, 2008) have demonstrated differences in HRV as a result of varying methods of
measuring heart rate (e.g., supine vs. standing. vs. tilting vs. 24-hour). Overall, the
current study will provide additional and more robust evidence into the effects of
Donepezil on cardiac autonomic function in persons with AD.
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CHAPTER III
METHODS AND PROCEDURE
Participants
Recruitment for the present study was completed in February, 2015. There were
two groups in which individuals were recruited; an Alzheimer’s Disease (AD) group and
a healthy control group. The AD group is comprised of individuals who were newly
diagnosed with probable AD of mild to moderate severity as reflected by Mini Mental
State Examination (MMSE) scores between 16 and 28. The AD group consists of
individuals taking Donepezil. AD participants were not taking Donepezil for longer than
3 months at Session 1. Doses of Donepezil were flexible and typically ranged from 5mg
to 10mg (after titration). The therapeutic dose may differ for each individual as dose is
based on the physician’s discretion. If participants discontinued Donepezil at any point
during the study, they were no longer eligible to participate. The healthy control group
consists of individuals who were not diagnosed with AD or any other type of cognitive
disorder, and who were not taking Donepezil. The Healthy Control group self-reported to
be free from cognitive impairment and obtained MMSE scores within the normal range
(27-30; Crum, Anthony, Bassett, & Folstein, 1993). Both groups were matched for
gender as well as age (± 3 years). This matching process is similar to that used by Stein et
al (1997) who successfully matched male and female older adult participants (± 3 years)
to study the differing effects of age on HRV between men and women. AD participants
were matched with a healthy control on an ongoing basis.
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All participants recruited for the study had at least a 6th grade education level,
which was ascertained during the phone screen. Probable AD was diagnosed according to
the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). All
participants were free from the following conditions: severe and chronic diseases
affecting general health (e.g., treatment for cancer [within the past year], diagnosed
cardiovascular disease, chronic kidney or liver disease (end stage renal disease requiring
dialysis), stroke or cerebrovascular events or disease, or brain tumors. Participants were
all fluent in English, and did not have any current substance dependence (based on DSM5 criteria). Participants were not taking other cholinesterase inhibitors, N-Methyl-Daspartate (NMDA) receptor antagonists (e.g., Namenda), anti-psychotics, anticonvulsants
or tricyclic antidepressants as these medications could interfere with the measures used in
this study. Participants were not diagnosed with severe psychiatric disorders such as
psychotic disorders, schizophrenia, or bipolar disorder. Lastly, participants did not have a
history of multiple head injuries, traumatic brain injury or multiple losses of
consciousness.
For sessions 1 and 2, the AD group (n= 12) and the healthy control group (n= 12)
were larger than the AD group (n= 8) and the healthy control group (n= 8) in session 3.
This was largely due to attrition rates and user error/unrecoverable data among the AD
group. More specifically, one AD participant (n= 1) withdrew from the study due to the
worsening of AD symptoms (cognitive decline) and a second AD participant (n= 1)
withdrew from the study due to adverse medication reactions which resulted in the
discontinuation of Donepezil (Aricept®). HRV data from two AD participants (n= 2)
were lost due to technological difficulties with the receiver (transferring the data to a PC
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failed) as well as user error (failure to capture the correct HRV time-interval data).
Therefore, two separate series of group analyses were conducted. In the first group of
HRV analyses, the AD group (n= 12) were compared to the healthy control group (n=
12) over a period of three months (session 1 and session 2; N= 24). In the second set of
HRV analyses, the AD group (n= 8) were compared to the healthy control group (n= 8)
over six months (session 1, session 2, and session 3; N= 16).
In the first set of HRV analyses (N= 24), the AD group consisted of seven males
(Mean age = 75.71, SD= 6.99) and five females (Mean age = 73.80, SD= 6.14) who were
matched with the healthy control group based on age and gender. Therefore, the healthy
control group also consisted of seven males (Mean age = 75.14, SD= 7.43) and five
females (Mean age = 73.00, SD= 5.70) of similar respective age. In the second set of
HRV analyses (N= 16), the AD group consisted of five males (Mean age = 77.20, SD=
6.26) and three females (Mean age = 70.33, SD= 5.51) who were again matched with the
healthy control group based on age and gender. Therefore, the healthy control group also
consisted of five males (Mean age = 77.40, SD= 4.92) and three females (Mean age =
70.33, SD= 6.11) of similar respective age. The total number of participants recruited for
the present study for sessions 1, 2, and 3 (N= 16) exceeded the total sample size
generated by the power analysis for the supine position. The total number of participants
recruited for the present study for sessions 1, 2, and 3 (N= 16) were equal to the total
sample size generated by the power analysis for the standing position (please refer to the
Power Analysis Section in Appendix G).
Recruitment. Participants diagnosed with probable AD were recruited from the
Glennan Center at Eastern Virginia Medical School (EVMS). The physicians were
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provided the eligibility criteria for the present study. If a patient met eligibility criteria for
the AD study, he/she was informed about the study and provided a verbal consent as to
whether or not they wanted to be contacted by a research team member. No study data
was obtained from the referring physicians. Flyers advertising for AD participants were
placed in the Glennan Center, offices of Internal Medicine, the Neuropsychology Center,
and public bulletin boards (PrimePlus senior center and the YMCA). All methods of
advertising received Internal Review Board (IRB) approval.
The age-matched healthy control group were recruited by local advertisement as
well as referrals from EVMS clinicians. Flyers advertising the need for volunteers were
placed in the offices of the Glennan Center, Internal Medicine, the Neuropsychology
Center, and public bulletin boards. Caregivers and local physicians were advised to give
the flyers to healthy individuals and/or individuals with recently diagnosed Alzheimer’s
disease that might be interested in participating in the study.
Once a potential participant provided a verbal consent to be contacted by a
member of the research team, a research assistant contacted the potential participant via
telephone and conducted a brief eligibility screen (see Appendix A). This included
questions surrounding Donepezil (Aricept®) use, the presence or history of
cardiovascular disease(s) or incidents (e.g., stroke), pertinent psychiatric history (e.g., a
history of schizophrenia or bipolar disorder), and medication use such as tricyclic antidepressants. If the participant was eligible for the study, he/she was invited to attend three
sessions at Eastern Virginia Medical School (EVMS), Department of Psychiatry and
Behavioral Sciences, located in Andrews Hall, Suite 244, Norfolk, Virginia. If an AD
participant was not able to attend the sessions at EVMS due to transportation issues (a
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common barrier for older adults with AD), the sessions were conducted in the
participant’s home. In-home sessions only took place if the participant lived within the
Hampton Roads area. All equipment was easily portable making this a very viable option.
All three sessions were completed in the same location to reduce the likelihood of the
environment impacting HRV recordings across sessions. Therefore, AD participants
either completed all three sessions in the home or at Eastern Virginia Medical School
(EVMS). A total of four AD participants completed all three HRV sessions in the home
environment. Participants in the healthy control group completed all sessions at EVMS.
Proposed Research Design and Methods
The present study has three specific hypotheses: 1) participants that are diagnosed
with mild to moderate AD and who are taking a stable dose of Donepezil (Aricept®) will
show increased parasympathetic nervous activity over a period of six months. This will
be indicated by decreases in LF Power (n.u.) and LF/HF Ratio in the standing position at
session 3 (six months) compared to session 1 (baseline). Thus, there will be a decrease in
LF Power (n.u.) and LF/HF Ratio from session 1 (baseline) to session 3 (six months)
when engaging in the orthostatic challenge (supine to standing). In contrast, HF Power
(n.u.) and RMSSD will increase in the standing position at session 3 (six months)
compared to session 1 (baseline). Therefore, there will be an increase in HF Power (n.u.)
and RMSSD from session 1 (baseline) to session 3 (six months) when engaging in the
orthostatic challenge (supine to standing); 2) Healthy controls will show significant
increases in HF Power (n.u.) from a supine to standing position at all three sessions. The
AD group will demonstrate minimal change in HF Power (n.u.) from a supine to a
standing position at the baseline session, but will show increased HF Power (n.u.) from
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supine to stand at sessions 2 and 3. Changes in HF Power (n.u.) from a supine to a
standing position at session 3 will be similar among both AD participants and healthy
controls; and 3) Donepezil (Aricept®) will improve parasympathetic nervous activity
through increased acetylcholine transmission, thus supporting the medications use as a
potential protective agent against cardiac autonomic dysfunction. This study will assess
heart rate variability (HRV) at baseline (initial session), three months after the first
session (session 2), and six months after first session (session 3). Each session will last
approximately 90 minutes in duration. Basic information such as height, weight, blood
pressure, body mass index (BMI), and heart rate variability measurements will be
obtained at each session. Again, the primary goal of the present research is to develop an
understanding of the relationship between cardiac autonomic function and AD while
identifying the cardiovascular effects of Donepezil on participants with AD.
Study Protocol
The present study obtained short-term time-domain (six minutes) and frequencydomain HRV data over the course of six months. HRV was obtained using a noninvasive
and reliable method that is widely used to measure cardiac autonomic function. More
specifically, Polar Performance Technology was utilized to evaluate overall cardiac
autonomic modulation including sympathetic and parasympathetic nervous system
function. HRV data were captured at baseline, three month, and six month intervals from
both AD and healthy control participants in both supine and standing positions as
recommended by the Task Force on Heart Rate Variability (1996). In order to obtain
HRV in a standing position, it was recommended that the participant sit in a resting
position prior to commencing the standing measurement (Risk, Broadbridge, & Cohen,
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2001). Obtaining HRV readings from a still resting position (supine) to a standing
position (orthostatic challenge) helped identify any significant changes in SNS and PNS
activity (Aysin & Aysin, 2007). In the present study, participants were seated in the
supine position for six minutes while an ECG was administered and HRV was obtained.
The participants then stood for six minutes and the ECG was re-administered for a second
time. Research suggests that the heart rate response to standing evaluates the
cardiovascular response initiated by a change from horizontal to a vertical position (Risk,
Broadbridge, & Cohen, 2001). The typical heart rate response to standing (increased
sympathetic activity) is largely mitigated by parasympathetic activity (Risk, Broadbridge,
& Cohen, 2001).
The potential impact of hypertension, obesity (BMI), exercise, caffeine use,
alcohol use, Aricept® dose, and related medications were tracked and evaluated in
tandem with the effects of Donepezil in the AD participants. This medical and lifestylebehavior information was collected for each participant at every session over the six
month period. All tests used in this protocol had been widely and safely used with diverse
populations (Allan et al., 2006; Da Costa Dias Dias, et al., 2013; Task Force on Heart
Rate Variability, 1996; Toledo & Junqueira, 2008). All necessary precautions were taken
during the course of participation to ensure the safety and wellbeing of the participant.
The protocol was carried out under the supervision of the principal investigator, Serina
Neumann, Ph.D. Although the risks associated with participation were minimal, adverse
events were reported in compliance with EVMS’s Internal Review Board (IRB) policies.
When a clinically significant physical or psychiatric disorder was identified during the
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course of participation, an appropriate referral to a medical or psychological treatment
facility was offered.
It is important to mention that the current study is part of a larger study exploring
the effects of Donepezil (Aricept®) on cardiac autonomic function and neuro-cholinergic
function among patients diagnosed with probable AD. In addition to the time- and
frequency-domain HRV measures discussed in the present study, neuropsychological
testing was also completed at the three month intervals. More specifically,
neuropsychological measures were obtained at baseline, three months and six months in
tandem with the respective HRV measures. Specific neuropsychological test measures at
these intervals included the Symbol Digit Modalities Test, Trails Making Tests A and B,
Controlled Oral Word Association Test, the Test of Premorbid Functioning (TOPF), and
Hopkins Verbal Learning Test. The same battery of testing was administered during all
sessions. However, for the purposes of this dissertation, the present study will primarily
explore Donepezil’s effect on cardiac function in patients with AD through an in vivo,
non-invasive measure of cardiac autonomic function.
Measures
Demographics/Socioeconomic Status (SES) form. This form was used to collect
demographic information such as age, gender, ethnicity, educational attainment, and job
and work history (see Appendix B). Age, gender, and ethnicity have been shown to
influence HRV (Stein, Kleiger, & Rottman 1997; Umetani, Singer, & McCraty, 1998)
and the Demographics/Socioeconomic Status (SES) form was used to capture this
information. These variables were then controlled for in the analyses.
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Lifestyle Behaviors Questionnaire. The lifestyle behaviors questionnaire was
used to collect information on lifestyle choices such as tobacco and alcohol use, daily
caffeine consumption, and hours of physical activity. The questions on this form were
compiled using selected questions from the following: SCID-NP (Structured Clinical
Interview

for

DSM-IV:

Non-patient

edition),

Paffenbarger

Physical

Activity

Questionnaire, and Tobacco use interview (see Appendix C). Alcohol use, tobacco use,
caffeine use, and physical activity can also interfere with HRV measures, and this
information was captured using the lifestyle behaviors questionnaire and controlled for in
the analyses (Harte & Meston, 2013; Hayano et al., 1990; Koskinen, Virolainen, &
Kupari, 1994; Molifino et al., 2009; Sandercock, Bromley, & Brodie, 2005;
Sondermeijer, Van Marle, Kamen, & Krum, 2002).
Medical History Checklist form. The medical history form was used to obtain
detailed information concerning the participant’s medical history. This included any
medical conditions surrounding the heart or blood vessels, the brain including
neurological conditions, and other diseases (see Appendix D). Participants were screened
for severe medical conditions prior to enrolling in the study and those with severe
medical conditions such as a recent history of stroke or a diagnosis of multiple sclerosis
were not be eligible to participate.
Medication Update Form. The medication update form was used to record and
follow changes in medication use and adherence to medical instructions during both
sessions. This included a list of all medications prescribed to participants, the prescribed
purpose, as well as the dosage and frequency. Information specific to the administration
of Donepezil was also gathered (see Appendix E). Certain medications such as beta-
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blockers and antihistamines can also effect blood pressure and HRV (Acharya et al.,
2006; Tinetti & Kumar, 2010). Therefore, these medication types and their prescribed
doses were controlled for in the analysis. If participants indicated that they had
discontinued Donepezil, they were no longer eligible to participate in the study.
Participants who reported adverse side-effects from their medications were referred to
their physician immediately. These adverse events were then reported in compliance with
EVMS’s Internal Review Board (IRB) policies.
Physical and Biological Assessments. The physical and biological assessments
were used to obtain the following: body mass index (BMI), blood pressure, and heart rate
variability. These data points were collected at all three sessions. Blood pressure was
obtained after the participant had been seated for five minutes (See appendix F). High
body mass index and high blood pressure have been shown to interfere with HRV
measures, and these were be captured by the physical and biological assessment and
subsequently controlled for in the analyses (Kleiger, Miller, Bigger, & Moss, 1986;
Kwon et al., 2008; Naver, Bloomstrand, & Wallin, 1996).
Measurement of HRV. HRV was measured from a continuous time series of
beat-to-beat intervals with Polar Performance Technology. Participants were required to
attach the Polar Performance sensor strap around their chest with the aid of a research
assistant to ensure the sensor was correctly placed. Participants were also required to
wear the Polar Performance receiver on their wrist. To estimate vagal activity precisely,
respiratory rate was assessed for one minute intervals at minute one and minute three of
the HRV recording. Respiration rate was captured by visual observation (rise and fall of
chest). Time and frequency-domain measures of HRV were recorded by the Polar
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Performance Technology. Time domain analyses provided the root mean of successive
differences in R-R intervals (RMSSD) and heart rate. Based on the Task Force on Heart
Rate Variability (1996), spectral analyses was performed on the beat-to-beat intervals
derived from the electrocardiogram (ECG) data collection to obtain both low frequency
(LF: 0.04-0.15 Hz) and high frequency (HF: 0.15-0.40 Hz) indices. As discussed in the
previous chapter, LF and HF Power bands measure differential autonomic nervous
system influences. HF Power primarily reflects respiratory-modulated parasympathetic
outflow, whereas LF frequency reflects sympathetic control and varying amounts of
parasympathetic influences (Toledo & Junqueira, 2008; Task Force on Heart Rate
Variability, 1996). LF Power is also thought to reflect baroreceptor-mediated regulation
of blood pressure (Bernston, et al., 1997; Friedman & Thayer, 1998). To interpret
sympathetic influences on the heart, an LF/HF ratio was computed to measure of
sympathovagal balance (Malliani, Lombard, Pagani, & Cerutii, 1990). This process was
completed for both supine and standing positions as LF Power in particular shows
significant changes when positioning is altered from a supine to a standing posture
(Acharya, et al., 2006; American Heart Association, 1996). Additionally, HRV has been
shown to vary as a function of gender, age, body mass index, high blood pressure,
caffeine use, heavy alcohol consumption, tobacco use, and physical activity, and these
factors were controlled for in the analyses if they correlated with HRV indices. More
information regarding the use of the HRV data can be found in the HRV data reduction
section below.
Data storage. All data were disassociated from participant’s names and other
identifying information by randomly assigning a four digit ID number. The connection
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relating the participant name with their ID number was held by the principal investigator
under lock and key and was destroyed after participant recruitment and data collection
was completed. Research staff training procedures also incorporated explicit instruction
regarding procedures for protecting participant confidentiality.
HRV Data Reduction
HRV data obtained from the Polar Performance Technology equipment during the
three sessions were screened for outliers and technological errors and these were
modified as needed. Once the data were checked for errors, average respiration rate
adjustments were made to the HF Power bands. The average number of respirations from
minute one and minute three were then divided by 60, and parameters were created by
adding and subtracting .03 (Berntson, et al., 1997). The HF Power band represented
Respiratory Sinus Arrhythmia (RSA). This data was then analyzed using the Kubios
HRV Analysis Software – Version 2.0 (Biosignal Analysis and Medical Imaging Group,
2008) which provided reports of HRV frequency-domains. Once these reports were
generated, data from the Autoregressive approach (AR) were used over the fast Fourier
transformation (FFT), as the AR method provides better frequency resolution than the
fast Fourier transformation (Malliani, Pagani, & Lombardi, 1994). The AR technique
concentrates on the more significant heart rate peaks which ultimately excludes
additional noise or interference (Berntson et al., 1997).
As recommended by the Task Force on Heart Rate Variability (1996), both LF
and HF Power bands were represented in normalized units (n.u.) which emphasizes the
controlled and balanced behavior of the sympathetic and parasympathetic nervous
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system. Normalized units are also advantageous as they minimize the effect of the change
in total power on the values of the LF and HF indices (Task Force on Heart Rate
Variability, 1996). The two normalized HRV power bands (LF Power n.u.) and (HF
Power n.u.) were then used to calculate the LF/HF ratio. The LF/HF ratio is a widely
used HRV index of sympathovagal balance between the two branches of the autonomic
nervous system (Burr, 2007). The LF/HF ratio is calculated by dividing the LF Power by
the LF plus the HF Power (Burr, 2007). Additionally, the square root of the mean of the
squared successive differences between adjacent R-R intervals (RMSSD) was analyzed,
which reflects the rapid beat-to-beat changes in intervals that are dependent on the
parasympathetic modulation associated with the respiratory sinus arrhythmia (RSA). For
each session (session 1 [baseline], session 2 [3 months], and session 3 [6 months])
averages from the HF Power n.u., LF Power n.u., RMSSD, and the LF/HF ratio were
computed for both the Alzheimer’s group and the healthy control group while in the
supine position and while standing (Toledo & Junqueira, 2008). These four HRV indices
in both standing and supine positions were compared across three different time frames in
separate analyses for both groups (between and within). Therefore, there were eight
different HRV dependent measures for each time point.
Statistical Analyses
Power analysis. A priori power analyses were conducted for both supine and
standing positions over three different time points. The power analysis was used to
determine an appropriate sample size to achieve adequate power to conduct the ANOVA
for the three hypotheses. Cohen’s d effect sizes were estimated for both supine and
standing positions from the Toledo & Junqueira (2008) cross sectional study evaluating
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HRV in AD patients. The Cohen’s d‘s were considered medium (d’s= .65) for the supine
AD high frequency power (n.u.) group mean (M= 0.28; SD= 0.03) and the control group
mean (M= 0.38; SD= 0.04; Cohen, 1988). The Cohen’s d’s were considered large (d’s =
.82) for the standing AD high frequency power (n.u.) group mean (M= 0.28 n.u.; SD=
0.03) and the control group mean (M= 0.34; SD= 0.04; Cohen, 1988). Given these effect
sizes and using a two-tailed alpha of .05, a power analysis was conducted with g*power
software (version 3.1.7). The results from the power analysis indicated that the total
number of participants required to obtain a similar effect size in the supine position for a
repeated measures, between-subjects, ANOVA would be 12. The total number of
participants required to obtain a similar effect size in the standing position for a repeated
measures, between-subjects, ANOVA would be 16 (see Appendix G).
Preliminary analyses. Preliminary analyses were conducted for two separate
samples. The first sample included participants from session 1 (baseline) and session 2 (3
months; N= 24) while the second analyses included participants from session 1
(baseline), session 2 (3 months) and session 3 (6 months; N= 16). Using SPSS software,
the preliminary analyses examined potential differences between the Alzheimer’s Disease
(AD) group and healthy controls on sample characteristics at session 1 (baseline), session
2 (3 months) and session 3 (6 months). This included age, gender, ethnicity, blood
pressure, body mass index, average hours of weekly exercise, medications (blood
pressure, allergy, anxiolytic or antidepressant), dose of Donepezil (Aricept®), average
weekly alcohol use, caffeine use (12 hours prior to HRV recording), exercise (12 hours
prior to HRV recording), and allergy medication (12 hours prior to HRV recording).
Though it was initially proposed that tobacco use would be examined, there were no
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current smokers in any group, and all previous smokers had been tobacco free for more
than 25 years. Therefore, this variable was removed from the analyses. Data were
checked for outliers, missing data points, skewness, and kurtosis. Normal distribution
was determined by calculating z-scores and dividing the skewness values by their
respective standard errors. If the absolute z-scores for skewness or kurtosis were larger
than 1.96 corresponding with a significant alpha level of < 0.05, these were considered
not-normal and subsequently transformed (Field, 2009). Both RMSSD and LF/HF Ratio
demonstrated numerous indices that were not normally distributed (i.e. skewed). As such,
all indices of RMSSD and LF/HF Ratio (supine and standing, sessions 1, 2, and 3) were
uniformly normalized by base 10 logarithm. Following these transformations, RMSSD
(log10) and LF/HF Ratio (log10) were re-checked for skewness and kurtosis and all were
considered to be normally distributed (skewness and kurtosis ratio = < 1.96; Field, 2009).
Once normal distribution among HRV indices was established, the HRV indices
were correlated with the following sample characteristics: age, gender, ethnicity, blood
pressure (systolic and diastolic), body mass index, average hours of weekly exercise,
medications (blood pressure, allergy, anxiolytic or antidepressant), dose of Donepezil,
average weekly alcohol use, caffeine use (12 hours prior to HRV recording), exercise (12
hours prior to HRV recording), and allergy medication (12 hours prior to HRV
recording). Pearson correlation coefficient non-parametric statistics were used for these
continuous/interval sample characteristics (e.g., HF Power and age). The sample
characteristics which were significantly correlated (p <.05) to any of the HRV indices
were controlled for in the ANCOVA analyses. To determine whether or not the
categorical (binomial) sample characteristics (gender, ethnicity, medication type [blood

61

pressure, allergy, anxiolytic or antidepressant], physical activity 12 hours before HRV
session, alcohol or caffeine use 12 hours before HRV session, and cold and allergy
medication 12 hours before HRV session) were correlated with the HRV indices, a
Kendell’s tau-b statistic was used. This was also recommended given the small sample
size used in this study (Field, 2009). Sample characteristics that were significantly
correlated with HRV indices (p= <.05) were controlled for in the ANCOVA model.
In order to identify between and within group differences among demographic
variables and sample characteristics, continuous variables were added to a repeated
measures ANOVA to test for independence. Continuous variables (e.g., average weekly
alcohol use) that showed significant between and within group differences were added to
the final ANCOVA model as covariates. Group differences among binomial variables
were identified using a chi-square test of independence. Those variables which were not
independent were added to the ANCOVA model as covariates. Lastly, using regression
analyses, the standardized residuals (variance) from the Aricept® dose were saved as
separate variables. The differences between the groups were considered statistically
significant when a p-value was equal or less than 5% (p < .05). The standardized
residuals were then correlated with the HRV indices using a Pearson correlation
coefficient non-parametric statistic. The standardized residuals from the Aricept® dose
that were significantly correlated with HRV indices were added to the final ANCOVA
model as covariates.
Primary analyses. Firstly, for the three hypothesis, a 2 (group [AD group versus
healthy controls]) x2 (task [supine to standing]) x2 (time [baseline and 3 month
intervals]) repeated measures analysis of covariance (ANCOVA) was computed. This
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analyses (2x2x2) tested the difference between the AD group versus the healthy control
group on the time- and frequency-domain HRV indices while engaging in the supine and
standing tasks over the course of three months. Secondly, a 2 (group [AD group versus
healthy controls]) x2 (task [supine to standing]) x3 (time [baseline, 3 month and 6 month
intervals]) repeated measures ANCOVA was computed. This analyses (2x2x3) tested the
difference between the AD group versus the healthy control group on the time- and
frequency-domain HRV indices while engaging in the supine and standing tasks over the
course of six months.
Each AD participant was successfully matched with a healthy control based on
age (± 3 years) and gender. The ANCOVA was used to control for the existing covariates
that were identified in the preliminary analysis. The LF Power (n.u.), HF Power (n.u.),
LF/HF Ratio (log10) and RMSSD (log10) obtained from the Alzheimer’s and healthy
control groups were compared across two and three different time points in both supine
and standing positions. Levene’s tests were checked for homogeneity of variance. For
those indices where the Levene’s tests were significant, the ratio of highest to lowest
variance was calculated. It is recommended that if the critical values of the variance
ratios are less than five, then the variance equality is considered acceptable (Field, 2009).
Variances for each HRV indices were calculated by squaring the standard deviations of
the HRV values. All HRV indices which showed Levene’s tests violations (p= <.05)
were considered acceptable based on the variance ratios.
Secondary analysis. Tukey’s HSD post-hoc tests for pairwise comparisons were
used to identify between and within group differences in the 2 (group [AD group versus
healthy controls]) x2 (task [supine to standing]) x2 (time [baseline and 3 month
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intervals]) repeated measures ANCOVA and the 2 (group [AD group versus healthy
controls]) x2 (task [supine to standing]) x3 (time [baseline, 3 month and 6 month
intervals]) repeated measures ANCOVA. Tukey’s HSD post-hoc tests were computed
using Tukey’s HSD post-hoc statistics software (Hall, 1998). The data from the
ANCOVA tables generated in SPSS for LF Power (n.u.), HF Power (n.u.), RMSSD
(log10) and LF/HF Ratio (log10) were transferred to this software. Separate Tukey’s
HSD post-hoc tests using the same processes were also conducted to identify any
significant within group differences from supine to standing.
Expected study findings. The expected findings of the present study include the
following: 1) participants that are diagnosed with mild to moderate AD and who are
taking a stable dose of Donepezil (Aricept®) will show increased parasympathetic
nervous activity over a period of six months. This will be indicated by decreases in LF
Power (n.u.) and LF/HF Ratio (log10) in the standing position at session 3 (six months)
compared to session 1 (baseline). Thus, there will be a decrease in LF Power (n.u.) and
LF/HF Ratio (log10) from session 1 (baseline) to session 3 (six months) when engaging
in the orthostatic challenge (supine to standing). In contrast, HF Power (n.u.) and
RMSSD (log10) will increase in the standing position at session 3 (six months) compared
to session 1 (baseline). Therefore, there will be an increase in HF Power (n.u.) and
RMSSD (log10) from session 1 (baseline) to session 3 (six months) when engaging in the
orthostatic challenge (supine to standing); 2) Healthy controls will show significant
increases in HF Power (n.u.) from a supine to standing position at all three sessions. The
AD group will demonstrate minimal change in HF Power (n.u.) from a supine to a
standing position at the baseline session, but will show increased changes in HF Power
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(n.u.) from supine to standing at sessions 2 and 3. Changes in HF Power (n.u.) from a
supine to a standing position at session 3 will be similar among both AD participants and
healthy controls; and 3) Donepezil (Aricept®) will improve parasympathetic nervous
activity through increased acetylcholine transmission, thus supporting the medications
use as a potential protective agent against cardiac autonomic dysfunction. If these
hypotheses are not met, this suggests that Donepezil may not possess the cardioprotective qualities that were initially expected, and the medication may not improve
cholinergic resources to the extent of enhancing cardiac autonomic function. These
results would be consistent with the results obtained by Masuda & Kawamura (2003),
McLaren et al (2003), and Siepmann et al (2006) who indicated a decrease in HF Power
as result of taking the medication Donepezil. Additionally, if there are no changes in HF
Power (n.u.) from a supine to a standing position at sessions 2 and 3, this will provide
further evidence that Donepezil does not possess adequate cardio-protective properties.
Furthermore, increases in LF Power (n.u.) and a higher LF to HF ratio may indicate the
continued dominance of the sympathetic nervous system and the presence of
parasympathetic depression despite the use of Donepezil. More specifically, this will
indicate a decrease in sympathovagal balance to reflect greater sympathetic modulation.
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CHAPTER IV
RESULTS
Table 1 summarizes demographic information for the 2 (group [AD group versus
healthy control group]) x2 (task [supine to standing]) x2 (time [baseline and 3 month
intervals]) repeated measures ANCOVA. Demographic variables which were correlated
with HRV indices are denoted by p–values.

Table 1. Descriptive Statistics and HRV Index Correlations of the AD and HC Sample for
the 2x2x2 ANCOVA (N= 24).
Demographic

AD

HC

Total Number of Participants

n= 12

n= 12

Gender

p

*
Male (n)

7

7

Female (n)

5

5

M (SD)

75.71 (6.99)

75.14 (7.43)

Female M (SD)

73.80 (6.14)

73.00 (5.70)

Age (years)
Male

Ethnic Background
Caucasian (n)

*
8

10

Male (n)

6

7

Female (n)

2

3

4

2

Male (n)

1

0

Female (n)

3

2

African-American (n)
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Table 1. Continued
p values were derived from the Pearson correlation coefficients and Kendall’s tau-b
statistic. Demographics with significant p values are correlated with one or more of the
HRV indices. Note: *p <.05

Tables 2 and 3 display sample characteristics for the 2 (group [AD group versus
healthy control group]) x2 (task [supine to standing]) x2 (time [baseline and 3 month
intervals]) analyses. Sample characteristics that were correlated with HRV indices or
showed significant group differences are denoted by p-values. Results from the Pearson
correlation coefficient and Kendall’s tau-b statistic indicated that gender and ethnicity
were correlated with LF Power (n.u.), HF Power (n.u.), and LF/HF Ratio (log10; p=
<.05). Body mass index was correlated with all four HRV indices (p= <.05) and allergy
medication was correlated with RMSSD (log10) only (p= <.05). Therefore, these
variables were included as covariates in the preliminary ANCOVA. Between group
differences in weekly alcohol consumption were also identified using a repeated
measures ANOVA F(1,22) = 6.95, p = .015, 95% CI [2.38, 7.31], η2 = .240. This variable
was also included in the ANCOVA model as a covariate.

Table 2. Sample Characteristics and HRV Index Correlations for the AD Group (n= 12).
Characteristic

Baseline (S1)

3 Months (S2)

p

Body Mass Index (kg) M (SD)

26.60 (5.59)

27.73 (6.46)

*

Blood Pressure Systolic (mmHg) M (SD)

139.92 (16.72)

130.83 (15.68)

75.92 (6.68)

74.00 (8.64)

Dose of Aricept (mg/day)

5.00

10.00

Blood Pressure Medication Taken (n)

9

9

Allergy Medication Taken (n)

0

2

Anxiolytic or Antidepressant Taken (n)

4

3

Number Alcoholic Drinks Per Week (Avg) M
(SD)

2.08 (6.01)

1.33 (4.03)

Hours Exercise Per Week (Avg) M (SD)

3.85 (3.36)

4.54 (4.04)

Alcohol or Caffeine last 12 hrs (n)

0

3

Exercise last 12 hrs (n)

0

0

Allergy Meds last 12 hrs (n)

0

1

Diastolic (mmHg) M (SD)

**

**

p values were derived from the Pearson correlation coefficients, Kendall’s tau-b correlation coefficients, and Analysis of
Variance. Sample characteristics with significant p values are correlated with one or more HRV indices. Note: *p <.05 **p
<.01
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Table 3. Sample Characteristics and HRV Index Correlations for the HC Group (n= 12).
Characteristic

Baseline (S1)

3 Months (S2)

p

Body Mass Index (kg) M (SD)

26.25 (5.15)

26.49 (5.49)

*

Blood Pressure Systolic (mmHg) M (SD)

134.75 (22.54)

127.75 (16.30)

76.58 (12.13)

75.33 (8.09)

Blood Pressure Medication Taken (n)

6

7

Allergy Medication Taken (n)

1

1

Anxiolytic or Antidepressant Taken (n)

1

1

Diastolic (mmHg) M (SD)

Number Alcoholic Drinks Per Week (Avg) M (SD) 6.92 (5.39)

7.04 (6.00)

Hours Exercise Per Week (Avg) M (SD)

8.58 (5.10)

5.29 (3.58)

Alcohol or Caffeine last 12 hrs (n)

4

1

Exercise last 12 hrs (n)

1

2

Allergy Meds last 12 hrs (n)

1

0

**

**

p values were derived from the Pearson correlation coefficients, Kendall’s tau-b correlation coefficients, and Analysis of
Variance. Sample characteristics with significant p values are correlated with one or more HRV indices. Note: *p <.05 ** p
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Table 4. Mean and Standard Error of Heart Rate Variability Indices in Healthy Control and Alzheimer’s Disease Groups in
Supine and Standing Positions at Baseline (Session 1) and Three Month (Session 2) Intervals.
Baseline (S1)
AD
HRV Measure

M

SE

3 Months (S2)
HC

M

AD
SE

M

HC
SE

M

SE

p

η2

Supine:
Low Frequency (n.u.)

58.03 ± 6.66

60.16 ± 8.27

65.61 ± 7.36

68.98 ± 5.32

.330

.056

High Frequency (n.u.)

41.97 ± 6.66

32.91 ± 7.15

34.39 ± 7.36

31.02 ± 5.32

.617

.015

RMSSD (log 10)

1.73 ± 0.14

1.43 ± 0.14

1.53 ± 0.19

1.52 ± 0.12

.864

.002

LF/HF Ratio (log10)

0.19 ± 0.15

0.19 ± 0.15

0.45 ± 0.21

0.43 ± 0.13

.254

.072

Low Frequency (n.u.)

72.10 ± 6.63

63.19 ± 5.77

72.25 ± 6.55

68.58 ± 6.36

.330

.056

High Frequency (n.u.)

27.90 ± 6.63

36.81 ± 5.77

27.75 ± 6.55

31.42 ± 6.36

.617

.015

RMSSD (log 10)

1.46 ± 0.18

1.54 ± 0.11

1.49 ± 0.23

1.38 ± 0.11

.864

.002

LF/HF Ratio (log10)

0.61 ± 0.19

0.32 ± 0.14

0.62 ± 0.20

0.45 ± 0.15

.254

.072

Standing:
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The data for the heart rate variability 2 (group [AD group versus healthy control
group]) x2 (task [supine to standing]) x2 (time [baseline and 3 month intervals])
ANCOVA analyses are presented in Table 4. Based on the ANCOVA, no indices showed
statistically significant between group differences from supine to standing (see Table 4).
However, the AD group displayed a trend towards relative sympathetic exacerbation
from supine to standing at both time points. This was indicated by increases in LF Power
(n.u.) from supine to standing at baseline and three months. The healthy control group
also demonstrated an increase in LF Power (n.u.) from supine to standing at baseline and
three months but to a smaller magnitude (see figure 1). The AD group demonstrated
lower levels of LF Power (n.u.) in the supine position at both time points in comparison
to the healthy controls. As expected, the sympathetic exacerbation from supine to
standing among the AD group was accompanied by relative parasympathetic depression
in comparison to the healthy control group. Among the AD group, this was indicated by
decreases in HF Power (n.u.) from supine to standing at baseline and supine to standing
at three months. In comparison, the healthy control group demonstrated parasympathetic
enhancement as evidenced by increased HF Power (n.u.) from supine to standing at
baseline and stable HF Power (n.u.) from supine to standing at three months (see figure
2). Consistent with lower levels of LF Power (n.u.), the AD group demonstrated higher
levels of HF Power (n.u.) in the supine position in comparison to healthy controls at both
time points.
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Figure 1. Supine to standing mean low frequency power (n.u.) for the AD and HC group
at baseline (S1) and 3 months (S2).

High Frequency Power (n.u.)

60
50
40

AD

30

HC
20
10
0

S1 Supine

S1 Standing

S2 Supine

S2 Standing

Figure 2. Supine to standing mean high frequency power (n.u.) for the AD and HC group
at baseline (S1) and 3 months (S2).

72
The relative sympathetic dominance in the standing position among the AD group
was also reflected by larger LF/HF Ratio (log10). More specifically, the degree in which
the LF/HF Ratio (log10) for the AD group increased from supine to standing at baseline
and supine to standing at three months was incrementally larger than the healthy control
group. In comparison, the healthy control group demonstrated increases in sympathetic
nervous activity from supine to standing at baseline and supine to standing at three
months, but to a lower magnitude (see figure 3). As expected, the AD group showed
reductions of a larger magnitude in the mean squared differences of successive R-R
intervals (RMSSD [log10]) from supine to standing at baseline in comparison to the
healthy control group who showed an increase in RMSSD (log10) from supine to
standing. Interestingly, this was not the case at the three month time period. At this time
interval, the healthy control group demonstrated smaller magnitudes of RMSSD (log10)
from supine to standing in comparison to the AD group (see figure 4). Larger magnitudes
of RMSSD (log10) among the AD group in the supine position at sessions 1 and 2 in
comparison to healthy controls were also reflective of greater HF Power (n.u.) at these
time points. Consistent with greater HF Power (n.u.) in the supine position, the AD group
showed a greater magnitude of RMSSD (log10) at both points and a slightly smaller
magnitude of LF/HF Ratio (log10) at session 2. Secondary analyses using Tukey’s posthoc tests did not reveal any significant between or within group differences for the 2
(group [AD group versus healthy control group]) x2 (task [supine to standing]) x2 (time
[baseline and 3 month intervals]) ANCOVA’s
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0.9
0.8

LF/HF Ratio (log10)
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AD

0.4

HC

0.3
0.2
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0

S1 Supine

S1 Standing

S2 Supine

S2 Standing

Figure 3. Supine to standing mean LF/HF Ratio (log10) for the AD and HC group at
baseline (S1) and 3 months (S2).
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Figure 4. Supine to standing mean RMSSD (log10) for the AD and HC group at baseline
(S1) and 3 months (S2).
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Table 5 summarizes demographic information for the 2 (group [AD group versus
healthy control group]) x2 (task [supine to standing]) x3 (time [baseline, 3 month and 6
month intervals]) ANCOVA analyses. Demographic variables which were correlated
with HRV indices are denoted by p–values.

Table 5. Descriptive Statistics and HRV Index Correlations of the AD and HC Sample for
the 2x2x3 ANCOVA (N= 16).
Demographic

AD

HC

Total Number of Participants

n= 8

n= 8

Gender

p

*
Male (n)

5

5

Female (n)

3

3

Age (years)
Male

**
M (SD)

77.20 (6.26)

77.40 (4.93)

Female M (SD)

70.33 (5.51)

70.33 (6.11)

Ethnic Background
Caucasian (n)

*
6

7

Male (n)

5

5

Female (n)

1

2

2

1

Male (n)

0

0

Female (n)

2

1

African-American (n)

p values were derived from the Pearson correlation coefficients and Kendall’s tau-b
statistic. Demographics with significant p values are correlated with one or more of the
HRV indices. Note: *p <.05 ** p <.01
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Tables 6 and 7 display sample characteristics for the 2 (group [AD group versus
healthy control group]) x2 (task [supine to standing]) x3 (time [baseline, 3 month and 6
month intervals]) analyses. Sample characteristics that were correlated with HRV indices
or showed significant group differences are also denoted by p-values. Results from the
Pearson correlation coefficient and Kendall’s tau-b statistic indicated that gender was
correlated with all four HRV indices (p= <.05) while age was correlated with LF Power
(n.u.), HF Power (n.u.) and LF/HF Ratio (log10; p= <.01). Ethnicity was only correlated
with LF Power (n.u.) while body mass index was correlated with LF Power and LF/HF
Ratio (log10; p= <.05). Systolic blood pressure was correlated with RMSSD (log10)
while Aricept® dose was correlated with RMSSD (log10) and LF/HF Ratio (log10; p=
<.05). Anxiolytic and antidepressant medications were correlated with HF Power (n.u.),
LF Power (n.u.) and LF/HF Ratio (log10; p= <.05). Lastly, average number of hours of
exercise per week was correlated with LF Power (n.u.), HF Power (n.u.), and LF/HF
Ratio (log10; p= <.05). Therefore, these variables were included as covariates in the
ANCOVA’s. Between group differences in weekly alcohol consumption were also
identified using a repeated measures ANOVA F(1,14) = 7.62, p = .015, 95% CI [2.52,
7.28], η2 = .352. This variable was also included in the ANCOVA model as a covariate.

Table 6. Sample Characteristics and HRV Index Correlations for the AD Group (n= 8).
Characteristic

Baseline (S1)

3 Months (S2)

6 Months (S3)

p

Body Mass Index (kg) M (SD)

25.86 (5.99)

26.56 (5.58)

25.49 (5.25)

*

Blood Pressure Systolic (mmHg) M (SD)

139.88 (19.50)

132.63 (15.70)

127.38 (17.86)

*

75.00 (7.46)

75.63 (7.96)

72.00 (8.30)

Dose of Aricept (mg/day)

5.00

10.00

10.00

Blood Pressure Medication Taken (n)

6

6

5

Allergy Medication Taken (n)

0

2

2

Anxiolytic or Antidepressant Taken (n)

2

1

1

*

Number Alcoholic Drinks Per Week (Avg) M (SD)

3.13 (7.28)

2.00 (4.90)

0.38 (0.74)

*

Hours Exercise Per Week (Avg) M (SD)

4.96 (3.53)

5.81 (4.21)

5.47 (2.63)

*

Alcohol or Caffeine last 12 hrs (n)

0

3

0

Exercise last 12 hrs (n)

0

0

0

Allergy Meds last 12 hrs (n)

0

0

1

Diastolic (mmHg) M (SD)

*

p values were derived from the Pearson correlation coefficients, Kendall’s tau-b statistic, and Analysis of Variance. Sample
characteristics with significant p values are correlated with one or more of the HRV indices. Note: *p <.05
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Table 7. Sample Characteristics and HRV Index Correlations for the HC Group (n= 8).
Characteristic

Baseline (S1)

3 Months (S2)

6 Months (S3)

p

Body Mass Index (kg) M (SD)

25.03 (5.20)

25.18 (5.50)

24.79 (5.06)

*

Blood Pressure Systolic (mmHg) M (SD)

135.50 (24.58)

126.75 (15.49)

129.13 (16.66)

*

75.50 (11.61)

74.88 (6.33)

75.50 (8.38)

Blood Pressure Medication Taken (n)

4

5

3

Allergy Medication Taken (n)

1

1

0

Anxiolytic or Antidepressant Taken (n)

1

1

1

*

Number Alcoholic Drinks Per Week (Avg) M (SD)

8.50 (5.15)

8.00 (4.96)

7.31 (5.38)

*

Hours Exercise Per Week (Avg) M (SD)

9.00 (4.17)

5.81 (4.09)

6.38 (3.29)

*

Alcohol or Caffeine last 12 hrs (n)

3

1

1

Exercise last 12 hrs (n)

1

1

1

Allergy Meds last 12 hrs (n)

1

0

0

Diastolic (mmHg) M (SD)

p values were derived from the Pearson correlation coefficients, Kendall’s tau-b statistic, and Analysis of Variance. Sample
characteristics with significant p values are correlated with one or more of the HRV indices. Note: *p <.05
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Table 8. Mean and Standard Error of HRV Indices in Healthy Control and Alzheimer’s Disease Groups in Supine and
Standing Positions at Baseline, Three Month, and Six Month Intervals.
Baseline (S1)
AD
HRV Measure

M

3 Months (S2)
HC

SE

M

SE

AD
M

6 Months (S3)

HC
SE

M

AD
SE

M

HC
SE

M

SE

p

η2

Supine:
Low Frequency
(n.u.)

52.43 ± 8.26 69.04 ± 6.07

63.49 ± 10.15 60.35 ± 5.59 60.76 ± 7.76

61.08 ± 5.79 .415

.097

High Frequency
(n.u.)

47.58 ± 8.27 30.96 ± 6.07

36.51 ± 10.15 39.65 ± 5.59 39.24 ± 7.76

38.91 ± 5.78 .339

.102

RMSSD (log 10)

1.82 ± 0.19

1.29 ± 0.16

1.59 ± 0.23

1.66 ± 0.12 1.83 ± 0.19

1.53 ± 0.12 .442

.060

LF/HF Ratio (log10)

0.43 ± 0.19

0.19 ± 0.14

0.37 ± 0.25

0.23 ± 0.14 0.23 ± 0.17

0.22 ± 0.12 .051

.440

Standing:
Low Frequency
(n.u.)

67.90 ± 7.56 58.63 ± 6.27

66.44 ± 8.76

65.70 ± 7.18 74.00 ± 7.41

65.04 ± 7.76 .415

.097

High Frequency
(n.u.)

32.10 ± 7.56 41.38 ± 6.27

33.56 ± 8.76

34.30 ± 7.18 26.00 ± 7.40

34.93 ± 7.66 .339

.102

RMSSD (log 10)

1.63 ± 0.23

1.54 ± 0.14

1.63 ± 0.26

1.40 ± 0.15

1.59 ± 0.20

1.47 ± 0.17 .442

.060

LF/HF Ratio (log10)

0.43 ± 0.19

0.19 ± 0.14

0.49 ± 0.26

0.34 ± 0.16

0.64 ± 0.24

0.40 ± 0.21

.440

.051
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The data for the heart rate variability 2 (group [AD group versus healthy control
group]) x2 (task [supine to standing]) x3 (time [baseline, 3 month and 6 month intervals])
analyses are presented in Table 8. Results from the 2 (group [AD group versus healthy
controls]) x2 (task [supine to standing]) x3 (time [baseline, 3 month and 6 month
intervals]) ANCOVA’s, did not demonstrate statistically significant between group
differences from supine to standing. As in the 2 (group [AD group versus healthy control
group]) x2 (task [supine to standing]) x2 (time [baseline and 3 month intervals]) analyses,
between group differences among LF Power (n.u.), HF Power (n.u.), LF/HF Ratio
(log10) and the mean squared differences of successive R-R intervals (RMSSD [log10])
were not statistically significant. There were no significant within group differences
among the HRV indices from supine to standing at the three time points. Despite the lack
of statistical significance, the AD group demonstrated a trend towards larger increases in
LF Power (n.u.) from supine to standing in comparison to the healthy control group at all
three sessions. The healthy control group demonstrated lower levels of sympathetic
exacerbation from supine to standing at session 1, supine to standing at session 2, and
supine to standing at session 3 in comparison to the AD group. Additionally, the level of
LF Power (n.u.)/sympathetic nervous activity exacerbated over time for the AD group in
comparison to the healthy control group which remained relatively stable. Results from
the 2 (group [AD group versus healthy control group]) x2 (task [supine to standing]) x3
(time [baseline, 3 month and 6 month intervals]) ANCOVA also indicated that the
healthy control group demonstrated higher levels of LF Power (n.u.) and lower levels of
HF Power (n.u.) in the supine position at sessions 1 and 3 compared to the AD group, but
once the AD group initiated the standing task, their LF Power (n.u.) exacerbated at a
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much larger rate than the healthy control group (see figure 5). As expected, the increase
in LF Power (n.u.) resulted in a decrease in HF Power (n.u.) among both groups with the
exception of the healthy control group at baseline who demonstrated an increase in HF
Power (n.u.) from supine to stand. Overall, the AD group demonstrated a higher
magnitude of parasympathetic depression in comparison to the healthy control group at
all three time points when engaging in the orthostatic challenge (supine to standing; see
figure 6).

Figure 5. Supine to standing mean low frequency power (n.u.) for the AD and HC group
at baseline (S1), 3 months (S2), and 6 months (S3).
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Figure 6. Supine to standing mean high frequency power (n.u.) for the AD and HC group
at baseline (S1), 3 months (S2), and 6 months (S3).

Results from the 2 (group [AD group versus healthy control group]) x2 (task
[supine to standing]) x3 (time [baseline, 3 month and 6 month intervals]) ANCOVA did
not indicate significant between group differences for the LF/HF Ratio (log10) but were
very close F(1, 8) = 5.50, p = .051, 95% CI [0.19, 0.50], η2 = .440. Results from the
ANCOVA also indicated a medium effect for the LF/HF Ratio (log10) between group
differences. The mean LF/HF Ratio (log10) reflected greater sympathetic dominance
(larger LF/HF ratios) in both supine and standing positions at sessions 1, 2 and 3 among
the AD group in comparison to the healthy control group. When transitioning from
supine to standing position, the AD group demonstrated larger increases in LF/HF Ratio
(log10) as well (see figure 7). This is consistent with the relative sympathetic
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exacerbation and parasympathetic depression demonstrated by the AD group as
evidenced by increased LF Power (n.u.) from supine to standing and decreased HF Power
(n.u.) from supine to standing. Lastly, the AD group showed a larger magnitude of mean
squared differences of successive intervals (RMSSD [log10]) from supine to standing at
all three time points in comparison to the healthy control group. The greater magnitude of
RMSSD (log10) among the AD group is reflective of the larger variations in LF Power
(n.u.) and HF Power (n.u.) from supine to standing (see figure 8). Secondary analyses
using Tukey’s post-hoc tests revealed significant between group differences at baseline
for RMSSD (log10) between the AD group (M=1.82, SD= 0.54) and the healthy control
group (M=1.29, SD= 0.46) while in the supine position (p <.05).

Figure 7. Supine to standing mean LF/ HF Ratio (log10) for the AD and HC group at
baseline (S1), 3 months (S2), and 6 months (S3).
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Figure 8. Supine to standing mean RMSSD (log10) for the AD and HC group at baseline
(S1), 3 months (S2), and 6 months (S3).
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CHAPTER V
SUMMARY AND DISCUSSION
The goal of the present study was to explore the effects of Alzheimer’s disease
(AD) pathology on cardiac autonomic function for individuals diagnosed with AD and
taking the medication Donepezil (Aricept®). Previous research and epidemiological data
using HRV technology have indicated variable disturbances of autonomic function in
persons with AD (Allan, et al., 2007; Giubilei et al., 1998; Masuda & Kawamura, 2003;
Siepmann et al., 2006; Toledo & Junqueira, 2008; Zulli et al., 2005). More specifically,
cardiac autonomic dysfunction is prevalent among individuals with AD as reflected by
exacerbated sympathetic nervous activity and decreased parasympathetic nervous activity
(Allan et al., 2007; Giubilei et al., 1998; Masuda & Kawamura, 2003; Siepmann et al.,
2006; Toledo & Junqueira, 2008; Zulli et al., 2005). This sympathovagal imbalance
(sympathetic dominance) is a recognized risk factor for cardiovascular mortality,
characterized by higher risk of arrhythmias, parasympathetic depression, syncope, and
sudden death (Allan et al., 2007; Kleiger, Miller, Bigger, & Moss, 1986).
Prior research has indicated that the enhancement of sympathetic nervous activity
and parasympathetic depression among persons with AD is even more profound
following a shift from a supine to a standing position (Toledo & Junqueira, 2008). This
shift in position (known as the orthostatic challenge), is an excellent way to measure
cardiac autonomic dysfunction due to the increase in sympathetic nervous activity
triggered from the supine to standing movement (Aysin & Aysin, 2007).

85
As poor cardiovascular health appears to be a mechanism of AD pathology,
research looking into the potential cardiovascular benefits of cholinesterase inhibitors
(ChEls) has gained much interest (Da Costa Dias et al., 2013; Giubilei et al., 1998;
Masuda & Kawamura, 2003; McLaren et al., 2003; Nordstrom et al., 2013; Siepmann et
al., 2006; Umegaki & Khookhor, 2013). However, results from studies exploring the
cardio protective benefits of ChEls have been mixed (Da Costa Dias et al., 2013; Giubilei
et al., 1998; Masuda & Kawamura, 2003; McLaren et al., 2003; Siepmann et al., 2006;
Umegaki & Khookhor, 2013). These studies also contain various methodological
limitations including the use of a now discontinued ChEls (Giubilei et al., 1998), the
short duration of study (e.g., two weeks; McLaren, et al., 2003; Umegaki & Khookhor,
2013), measuring changes at a single, variable (± 4.8 weeks) time frame (Da Costa Dias
Dias et al., 2013), the use of animal subjects as opposed to human subjects (Umegaki &
Khookhor, 2013), the absence of normalized units when exploring changes in HRV over
time (Masuda & Kawamura, 2003; Toledo & Junqueira, 2008; Umegaki & Khookhor,
2013), the lack of a healthy control group comparison (McLaren, et al., 2003), and
controlling for few factors which have been shown to interfere with HRV measurement
(Da Costa Dias Dias et al., 2013; Giubilei et al., 1998; Masuda & Kawamura, 2003;
McLaren, et al., 2003; Siepmann et al., 2006; Umegaki & Khookhor, 2013).
In the present study, differences in HRV among individuals with Alzheimer’s
disease versus healthy controls were studied over a period of six months in both supine
and standing positions. HRV was obtained through the utilization of non-invasive
electrocardiogram (ECG) technology using frequency-domain (LF Power, HF Power,
RMSSD, LF/HF Ratio) and time-domain (six minutes) measures. The results of the
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current study indicated a trend towards greater reductions in parasympathetic function
and greater increases in sympathetic function among the AD group in comparison to the
healthy controls during the orthostatic challenge. This was the case across all three time
points. More specifically, the AD group showed a lower magnitude of normalized high
frequency power in comparison to healthy controls (session 1= 9.28% [lower]; session 2=
3.67% [lower]; session 3= 8.93% [lower]) while in the standing position. This trend was
accompanied by a greater LF/HF ratio among the AD group (session 1= 0.24% [greater];
session 2= 0.15% [greater]; session 3= 0.24% [greater]) reflecting greater sympathovagal
imbalance. Statistically, this trend towards greater LF/HF Ratio among the AD group
versus healthy controls at all three sessions also corresponded with a medium effect size
(95% CI [0.19, 0.50], η2 =.440). Therefore, Cohen’s effect size value suggested a
moderate level of practical significance, which is reflected by the large trend toward
sympathetic exacerbation among the AD group when engaging in the orthostatic
challenge. Despite this trend toward sympathetic exacerbation among the AD group
while engaging in the orthostatic challenge, it is important to note that the results from
the ANCOVA’s were not statistically significant. In addition, although there was a
medium effect size for the LF/HF ratio, it is important to consider the potentially large
amount of error variance that may be inherent with a small sample. Therefore, these
results need to be interpreted with caution.
During the supine task, the AD group showed a larger magnitude of normalized
high frequency power in comparison to the healthy control group (session 1= 16.62%
[greater]; session 2= 3.37% [greater]; session 3= 0.33% [greater]). However, this was
substantially reduced when engaging in the standing task (orthostatic challenge).
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Therefore, the supine position may mask the presence of cardiac autonomic dysfunction,
which is then revealed when the individual engages in the orthostatic challenge. While
engaging in the orthostatic challenge, the healthy control group showed an increase in
normalized high frequency power from supine to standing at session 1, indicating better
sympathovagal balance when changing posture. Not surprisingly, the healthy control
group demonstrated greater high frequency power at session 1 (9.28% [greater]) in
comparison to the AD group while engaging in the orthostatic challenge. At sessions 2
and 3, the healthy control group demonstrated a reduction in high frequency power from
supine to standing. However, the magnitude of the high frequency power generated by
the healthy control group while in the standing position at sessions 2 (3.67% [greater])
and 3 (8.93% [greater]) was still comparatively larger than the AD group. Therefore, the
healthy control group generated a greater magnitude of high frequency power at all three
sessions when engaging in the orthostatic challenge.
Based on a meta-analysis of short-term heart rate variability recordings among
healthy adults (≥ 18 years; Nunan, Sandercock, & Brodie, 2010), the mean normal values
of low frequency power (expressed in normalized units) should be approximately 52%
(SD= 10), while mean normal values of high frequency power (expressed in normalized
units) should be approximately 40% (SD= 10). While in the supine position, the AD
group generated more similar magnitudes of low and high frequency power with respect
to this normative sample. However, while engaging in the orthostatic challenge, the
healthy control group generated more similar magnitudes of low and high frequency
power with respect to this normative sample. This may provide further corroborating
evidence for more healthy cardiac autonomic function among the healthy control group
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while engaging in the orthostatic challenge. It is important to mention that the Nunan,
Sandercock, & Brodie (2010) study combined all HRV positions (e.g., supine and
standing) and did not provide separate mean scores for older adults. Therefore, the
conclusions that can be drawn between the data obtained in the present study and this
normative data are limited.
The results from the current study are similar to that of three previous studies that
identified a significant reduction in high frequency power among AD participants
undergoing ChEls treatment (McLaren et al., 2003; Siepmann et al., 2006; Masuda &
Kawamura, 2003). Additionally, the current study supports general findings from authors
Toledo & Junqueira (2008) and Zulli et al (2005) who identified relative parasympathetic
depression and sympathetic exacerbation among individuals with AD versus healthy
controls. However, AD participants in the Toledo & Junqueira (2008) study were not
undertaking ChEls treatment and also demonstrated parasympathetic depression and
sympathetic exacerbation in the supine position. Findings from the current study suggest
that individuals with AD who were taking the medication Donepezil (Aricept®) showed
better high frequency power in the supine position at sessions 1, 2 and 3 in comparison to
healthy controls. These findings may indicate that cardiac autonomic function is
improved among individuals with AD when in the supine position as a result of the
cholinesterase inhibitor Donepezil (Aricept®). However, when the AD participants are
standing, the potential beneficial effects of Aricept® appear to be minimized.
Previous research has demonstrated that changes in blood pressure, high and low
frequency band power show significant changes when positioning is altered from a
supine to a standing posture (Acharya, et al., 2006; American Heart Association, 1996;
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Aysin & Aysin, 2007). This was particularly evident among the AD group who showed
exacerbated low frequency power and reduced high frequency power from supine to
standing positions at all three time points in comparison to healthy controls. This
decrease in high frequency power among the AD group when engaging in the orthostatic
challenge may be a more accurate reflection of cardiac autonomic dysfunction given that
the orthostatic challenge is commonly used to measure ANS function (Aysin & Aysin,
2007). As there is a strong relation between the autonomic nervous system and blood
pressure via the baroreceptor reflex (the baroreceptor reflex helps restore blood pressure
by increasing heart rate), it is possible that the AD group experienced greater oscillations
in blood pressure (e.g., orthostatic hypotension) while engaging in the orthostatic
challenge (Berntson, 1997). Previous research has indicated a strong relation between
high blood pressure and greater low frequency power (sympathetic exacerbation) among
hypertensive individuals (Piccirillo, Munizzi, Fimognari, & Marigliano., 1996).
Although findings from the current study are similar to that of previous research
(Masuda & Kawamura, 2003; McLaren et al., 2003; Siepmann et al., 2006; Toledo &
Junqueira., 2008; Zulli et al., 2005), it is important to mention that these results also
contradict previous findings as well (Giubilei, et al., 1998). For example, authors Giubilei
et al (1998) identified improved cardiac autonomic function among individuals with AD
who were undertaking ChEl treatment. More specifically, the AD group showed similar
magnitudes of high frequency power and low frequency power compared to healthy
controls while in the tilting position following ChEl treatment. However, there were
various limitations to this study including the short time frame studied (one month) and
the use of a now discontinued ChEls. Overall, results from the present study extend the
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majority of the previous findings regarding autonomic dysfunction in persons with
Alzheimer’s disease and healthy older adults, reinforcing patterns of parasympathetic
depression and sympathetic exacerbation (Masuda & Kawamura, 2003; McLaren, et al.,
2003; Siepmann et al., 2006; Toledo & Junqueira, 2008, 2009; Zulli et al., 2005).
With regards to the expected findings outlined previously, the AD group showed
greater high frequency power at session 1 (16.62% [greater]), and slightly better high
frequency power at session 2 (3.37%[greater]) and session 3 (0.33% [greater]) in
comparison to the healthy control group in the supine position. Although the magnitude
of high frequency power at session 3 had decreased by 8.34% from session 1 for the AD
group, the magnitude of high frequency power was still larger than that of the healthy
control group at all three sessions while in the supine position. The larger proportion of
high frequency power generated by the AD group at baseline may be related to the
proximity to the first dose of Aricept® and the stabilization (therapeutic dose) of the
medication at the six month time point. More specifically, two previous studies have
indicated initial increases in high frequency power after short periods of ingestion of a
ChEls (two weeks and one month respectively; Giubilei et al., 1998; Umegaki &
Khookhor, 2013). This may be of particular significance because researchers Rogers et al
(1998) found that the effects of Donepezil on cognitive functioning were most
pronounced at the 12 week visit (three months). These neurocholinergic effects also
persisted with no decrease in magnitude at weeks 18 and 24 (Rogers, 1998). During the
baseline phase, AD participants were fairly early in their ChEl treatment (less than three
months) and were exposed to lower doses (5mg) of Aricept®. By session 2 (three
months) and session 3 (six months), AD participants were taking Aricept® for an
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extended period of time and were titrated to larger doses (10mg). Therefore, the results
from the current study may suggest that chronic administration of Aricept® could have
positive effects of PNS activity at the six month interval in comparison to healthy
controls through an increase in cholinergic resources. However, the AD group
demonstrated large reductions in high frequency power from baseline to six months
particularly in the standing position. Therefore, this suggests that participants diagnosed
with mild to moderate AD continued to show cardiac autonomic dysfunction over a
period of six months while taking Donepezil (Aricept®). Given that the orthostatic
challenge has been widely used as a measure of cardiac autonomic function, the results
demonstrating decreases in high frequency power among the AD group when in the
standing position appear to be more compelling.
Secondly, it was hypothesized that healthy controls would show significant
increases in high frequency power from a supine to standing position at all three sessions,
while the AD group would demonstrate minimal change in high frequency power from a
supine to standing position at the baseline session, but would gradually show increased
high frequency power from supine to standing at sessions 2 and 3. Results from this study
indicated that healthy controls demonstrated both increases in high frequency power from
supine to standing at session 1 (10.42% [increase]) and decreases in high frequency
power from supine to standing at sessions 2 (5.35% [decrease]) and 3 (3.98% [decrease]).
In contrast, the AD group showed larger decreases in high frequency power from supine
to standing at all three sessions (session 1= 15.48% [decrease]; session 2= 6.82%
[decrease]; session 3= 13.24% [decrease]). However, these results were not statistically
significant. The current HRV literature also indicates that healthy older adults have the
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tendency to show reductions in high frequency power from supine to standing positions
as well (Toledo & Junquiera, 2008). Although it was hypothesized that the healthy
controls would display increases in high frequency power from supine to standing, the
trend for reductions in high frequency power from supine to standing among the healthy
older adults at sessions 2 and 3 found in the present study are consistent with previous
findings (Giubilei, et al., 1998; Toledo & Junquiera, 2008).
Thirdly, it was hypothesized that Donepezil (Aricept®) would improve
parasympathetic nervous activity through increased acetylcholine transmission, thus
supporting the medications use as a potential protective agent against cardiac autonomic
dysfunction. Results from this study indicate that high frequency power was greater for
individuals with AD in comparison to healthy controls at sessions 1, 2 and 3 in the supine
position only. Therefore, it is possible that Donepezil (Aricept®) may provide cardioprotective factors which are more evident in the supine position. However, as mentioned
previously, the potential cardiac benefits of Donepezil (Aricept®) appear to be nullified
during a standing task. These results are consistent with the results obtained by Masuda
& Kawamura (2003) and McLaren et al (2003) who indicated a decrease in high
frequency power as result of taking the medication Donepezil. Increases in low frequency
power and a larger LF/HF ratio among the AD group also indicated the continued
dominance of the sympathetic nervous system and the presence of parasympathetic
depression despite the use of Donepezil. Thus, there is a tendency towards
sympathovagal imbalance reflecting greater sympathetic modulation during a supine to
standing task among the AD group.
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One of the goals of the present study was to address the methodological
limitations of studies exploring the effects of ChEls on HRV among individuals with AD.
Firstly, participants taking the medication Donepezil were matched with a healthy control
of the same age (± 3 years) and gender. The previous studies exploring the effects of
ChEl treatment on individuals with AD did not match AD participants with healthy
controls (Da Costa Dias et al., 2013; Masuda & Kawamura, 2003; McLaren, et al., 2003;
Umegaki & Khookhor, 2013). Secondly, the participants in the current study were taking
Donepezil for six months and data was obtained at three different time points (session 1
[baseline], session 2 [three months], and session 3 [six months]). Few studies have
examined the cardiovascular benefits of the medication after six weeks (Da Costa Dias et
al., 2013; Masuda & Kawamura, 2003; McLaren, et al., 2003; Siepmann et al., 2006;
Umegaki & Khookhor, 2013). Thirdly, the present study controlled for the following
confounds, which are known to influence HRV measures: age, gender, body mass index
(BMI), blood pressure (systolic and diastolic), medications (blood pressure, allergy,
anxiolytic or antidepressant), dose on Donepezil (Aricept®), alcohol use, caffeine use,
and physical activity (Harte & Meston, 2013; Hayano et al., 1990; Koskinen, Virolainen,
& Kupari, 1994; Molifino et al., 2009; Sandercock, Bromley, & Brodie, 2005;
Sondermeijer, Van Marle, Kamen, & Krum, 2002; Stein, Kleiger, & Rottman 1997;
Umetani, Singer, & McCraty, 1998). The results from the Pearson correlation coefficients
and the Kendall’s tau-b correlation coefficients demonstrated that age, body mass index,
blood pressure, medications (blood pressure, allergy, anxiolytic or antidepressant), dose
of Aricept, and physical activity all correlated with one or more of the HRV indices.
Significant between group differences in alcohol use were also identified from the
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between subjects ANOVA’s. Thus, it is probable that these factors could influence
variations in multiple HRV indices.
With regards to the statistical analyses, although there were fairly clear mean
differences in HRV indices and a large effect in LF/HF Ratio between the AD group and
the healthy control group, none of these mean comparisons were statistically significant.
As HRV is very sensitive to various confounding conditions, it is possible that some of
the variance in HRV in previous studies can be accounted for by these confounding
factors. For example, the Toledo & Junquiera (2008) study indicated significant
differences between individuals with AD and healthy controls from a supine to standing
position. However, the mean age of the AD group (Mean age= 79.6) was higher than the
age of the control group (Mean age= 68.6). Therefore, some of this between group
variance might be explained by age differences between the AD group and the healthy
control group.
Fourthly, some of the indices (low frequency power and high frequency power)
used in this study were reported in normalized units to emphasize the controlled and
balanced behavior of the sympathetic and parasympathetic nervous system (Task Force
on Heart Rate Variability, 1996). Normalized units display sympathetic and
parasympathetic activity as a percentage (0%-100%). This allows the clinician to easily
ascertain changes in sympathetic versus parasympathetic output over time (e.g., when
using a repeated measures design) but also provides the opportunity to determine
sympathetic versus parasympathetic modulation (Task Force on Heart Rate Variability,
1996). Previous studies have not utilized normalized units to monitor changes in HRV
among individuals with AD taking the medication Donepezil (Aricept®; Masuda &
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Kawamura, 2003; McLaren, 2003; Umegaki & Khookhor, 2013). Using normalized units
also provides the opportunity to compare HRV indices with normative data or previous
studies that express HRV data in normalized units.
Fifthly, respiration count was captured and added to the HRV algorithm using the
Kubios HRV Analysis Software. This was accomplished by observing the frequency of
breaths (rise and fall of the chest) at two separate one minute intervals (minute one and
minute three) during the supine and standing position at all three sessions. As discussed
previously, the adjustment using respiration in a HRV algorithm is known as respiratory
sinus arrhythmia (RSA). The RSA is generated by integrating changes in heart rate
during inhalation (heart rate increases) and exhalation (heart rate decreases). Respiratory
linked variations in heart rate usually occur in the high frequency range (Lehrer,
Vaschillo, and Vaschillo, 2000) and thus, RSA has been shown to provide a more
accurate index of cardiac vagal tone and parasympathetic activity (Grossman & Taylor,
2006). Finally, the present study obtained HRV measures in both supine and standing
positions as previous studies have demonstrated differences in HRV as a result of varying
methods of measuring heart rate (e.g., supine vs. standing. vs. tilting vs. 24-hour;
(Giubilei et al., 1998; Masuda & Kawamura, 2003; Siepmann et al., 2006; Toledo &
Junqueira, 2008; Zulli et al., 2005).
Clinical Implications for Health Psychology
Given the strong evidence for cardiac autonomic dysfunction among individuals
with AD as evidenced in the present study, HRV technology could be utilized to capture
sympathetic and parasympathetic nervous activity among patients who are at risk for
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developing AD (e.g., genetically or recently diagnosed with mild cognitive impairment).
Subsequent changes in HRV (e.g., low frequency dominance) in tandem with decreased
cognitive status could provide corroborating evidence for reductions in acetylcholine
production, transmission, and probable dementia. As results from this study demonstrated
large decreases in high frequency power during the orthostatic challenge among the AD
group, it is may be beneficial to obtain HRV recordings in two separate positions. More
specifically, when obtaining HRV data from individuals with suspected AD, HRV
recordings should be performed in both the supine and standing position as the orthostatic
challenge revealed greater cardiac autonomic dysfunction among the AD group when
changing position. If the clinician obtains HRV readings in the supine position only, then
the presence of cardiac autonomic dysfunction may be missed. Once the clinician obtains
HRV data, results could be communicated to the patient’s primary care physician and the
interdisciplinary care team who may use this information to guide treatment
interventions. For example, if the individual shows impaired cardiac autonomic function
via sympathetic dominance, referral to a health psychologist for HRV biofeedback,
relaxation training, or progressive muscle relaxation may reduce the risk for potential
cardiac events. Both relaxation training and progressive muscle relaxation exercises have
been successfully implemented with older adults (Hirokawa, 2004; Morone & Greco,
2007). One particular study significantly reduced hypertension among older adults using
guided relaxation training (Tang, Harms, Speck, Vezeau, & Jesurum, 2009).
Another clinical intervention that may reduce the likelihood of future cardiac
events is slow (diaphragmatic) breathing. Research has indicated that people are capable
of voluntarily producing substantial increases in respiratory sinus arrhythmia (RSA) or
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high frequency power using biofeedback techniques (Lehrer, Vaschillo, & Vaschillo,
2000). It is well established that HRV is systematically influenced by breathing
frequency, with higher frequency being generated by slower respiration (Lehrer &
Gevirtz, 2014). As such, when breathing rate is reduced, R–R interval fluctuations and
spectral power are increased (Eckberg, 2003). The recommended rate of breathing to
achieve increased R-R fluctuations and higher frequency output is six breaths per minute
(Lehrer & Gevirtz, 2014). In order to achieve a rate of six breaths per minute, a pacing
stimulus can be presented on a computer display screen prompting patients when to
slowly inhale and exhale using their diaphragm (diaphragmatic breathing; Lehrer,
Vaschillo, and Vaschillo, 2000). The introduction of HRV biofeedback technology then
teaches the patient to breathe approximately in phase with heart rate changes through a
different visual display (Lehrer, Vaschillo, & Vaschillo, 2000). According to a summary
of the HRV biofeedback literature by Wheat & Larkin (2010), HRV biofeedback has
been shown to significantly reduce cardiovascular mortality and hypertension in adults.
Progressive muscle relaxation and relaxation training in combination with HRV
biofeedback has also demonstrated reductions in cardiovascular risk and hypertension
among adults as well (Wheat & Larkin, 2010). This is highly pertinent given the relation
between AD and cardiac autonomic dysfunction, the high rate of cardiac events among
older adults, and the prevalence of hypertension among older adults.
Pharmacological interventions may also help to improve cardiac autonomic
function as well. Certain blood pressure medications such as antihypertensives (beta
blockers) have been shown to improve high frequency power and cardiac autonomic
function after eight weeks among adults diagnosed with hypertension (Pavithran,
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Prakash, Dutta, & Madanmohan, 2010). Therefore, individuals who present with
parasympathetic depression following a HRV recording may be referred to a physician
for a medication evaluation. The impact of the prescribed medication on the autonomic
nervous system could be easily monitored via standardized pre/post HRV recordings
using normalized units.
Other potential risk factors associated with cardiac autonomic dysfunction (e.g.,
parasympathetic depression) include an increased risk for falls (American Geriatrics
Society, 2010; Melillo, Jovic, De Luca, Morgan, & Pecchia, 2015). This is a major
problem for older adults as one in ten falls results in serious injury and up to one in five
in a fracture (Tinetti, 2003). Individuals with autonomic dysfunction and hypertension are
also at higher risk for experiencing postural (orthostatic) hypotension which is a wellknown risk factor for falls among the elderly (American Geriatrics Society, 2011). The
use of Donepezil has also been shown to cause orthostatic hypotension in some
individuals as well (Bordier, 2006). Orthostatic hypotension is defined as a decrease in
systolic blood pressure of 20 mmHg (or 20%) or more when the individual transitions
from a supine to standing position (Tinetti, 2010). In the present study, the AD group
showed greater increases in low frequency power compared to healthy controls when
engaging in the orthostatic challenge (supine to standing). Previous research has indicated
a relation between increased sympathetic nervous activity (low frequency power) and
hypertension (Melillo, Jovic, De Luca, Morgan, & Pecchia, 2015). Although blood
pressure was not measured in the standing position, it is possible that the AD group
experienced greater fluctuations in blood pressure (e.g., hypertension) following the
orthostatic challenge. Therefore, identifying cardiac autonomic dysfunction among older
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adults via non-invasive HRV measures and providing interventions to improve cardiac
autonomic function may reduce the likelihood of a fall. Interventions which have been
shown to reduce the likelihood of falls among older adults include medication
management, increased fluid intake, physical therapy (PT), increased exercise, and deep
breathing (American Geriatrics Society, 2011; Jáuregui-Renaud, Márquez, Hermosillo,
Sobrino, & Lara, et al., 2003).
Limitations of the Current Study and Suggestions for Future Studies
There are various limitations to the current study, which warrant discussion.
Firstly, although the sample size identified by the power analyses was met for both
supine and standing positions, previous studies have used slightly larger samples to
assess changes in HRV and obtained significant results (Da Costa Dias Dias et al., 2013;
Masuda & Kawamura, 2003; Siepmann et al., 2006; Toledo & Junquiera, 2008; Zulli, et
al., 2003). Results from the ANCOVA also indicated a medium effect for the LF/HF
Ratio (log10) between group differences. The mean LF/HF Ratio (log10) reflected
greater sympathetic dominance (larger LF/HF ratios) in both supine and standing
positions at sessions 1, 2 and 3 among the AD group in comparison to the healthy control
group.. However, based on the small sample used, this statistic was interpreted with
caution given the potential for error variance within a small sample. The results from the
present study do however indicate the need for larger controlled trials to further
investigate the cardiovascular effects of Donepezil. One of the drawbacks of the small
sample used in this study was the impact of variable scores on the mean of each HRV
index. Using a larger sample would reduce the likelihood of more variable scores
impacting the means of each index and increase the likelihood of detecting a statistical
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significance. Secondly, it is difficult to determine the extent to which Donepezil may
improve cardiac autonomic function compared to individuals with AD who are not taking
Donepezil. Having a third comparison group (an AD group who are not taking
Donepezil) or normative HRV data based on age, gender, and HRV positioning would
provide more information of the extent to which Donepezil impacts the trajectory of
cardiac autonomic dysfunction. However, recruiting individuals who are diagnosed with
AD and who are not taking a ChEls would be challenging as the large majority of
individuals diagnosed with probable AD are prescribed a cholinesterase inhibitor or a NMethyl-D-aspartate (NMDA) receptor antagonists (e.g., Namenda).
Thirdly, given the increase in sympathetic nervous activity from the supine to
standing position among individuals with AD, it is possible that baroreceptor reflex
sensitivity is diminished among this population. Obtaining a blood pressure reading from
AD participants in the standing position (e.g., measuring postural hyper/hypotension)
may help identify any interference in the participants homeostatic mechanisms that help
maintain blood pressure (Berntson, 1997). Fourthly, although transforming the RMSSD
and LF/HF Ratio HRV indices using base 10 logarithm reduced the skewness and
kurtosis of the distribution, interpretation of these indices became more difficult as the
values were no longer expressed in normalized units and ratio values (LF/HF Ratio).
However, Toledo & Junquiera (2008) used similar log transformations to correct nonnormal distribution among their HRV indices and used similar interpretations. Fifthly,
future studies may want to explore whether the combination of a ChEls and N-Methyl-Daspartate (NMDA) receptor antagonist (e.g., Namenda) improves HRV above and beyond
a ChEls alone. Sixthly, HRV was captured in the home environment for four of the AD
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participants. Although obtaining HRV in the home was advantageous for recruitment
purposes, this may have influenced HRV indices. Research has indicated that individuals
with white coat hypertension (high blood pressure in the clinical setting) have a tendency
towards higher levels of LF power and a propensity towards sympathovagal imbalance
(Fagard, Stolarz, Kuznetsova, Seidlerova, & Tikhonoff, 2007). Based on this research, it
is possible that individuals whose HRV was obtained in the clinical/laboratory setting
were more likely to experience greater low frequency power compared to individuals
whose HRV was captured in the home environment. Therefore this could be a potential
confound, which was not accounted for in this study design. In order to reduce this
confound in future studies, it is recommended that HRV be obtained in the same
environment across and within groups. Lastly, the inclusion of neurocognitive measures,
in addition to HRV measures, would provide a more accurate indication of the potential
cholinergic benefits of Donepezil (Aricept®). As mentioned previously, cholinergic
resources become increasingly deficient in individuals with AD resulting in
neurocognitive impairment (Miur, 1996). Furthermore, the use of biomarkers such as
volumetric magnetic resonance imaging (MRI) may help validate changes in HRV as a
result of ChEl treatment. Overall, it appears that Donepezil’s effect on cardiac function in
patients with Alzheimer’s disease is limited and requires further exploration.
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APPENDIX A
Phone Screen
Donepezil’s Effect on Cardiac Function in Patients with Alzheimer’s Disease
Through an In Vivo, Non Invasive Measure of Peripheral Neuro-cholinergic
Function: Relation to Therapeutic Efficacy
Name:___________________________
To be read to subject before screening questions: We are calling from Eastern
Virginia Medical School regarding the research study that you expressed interest in. We
wanted to see if you would be interested in participating in a research study that is
examining the relation between heart and brain function and potential effects of
medications on these functions. Your involvement in the study would last for 6 months
with a total commitment of about 5 hours over that time. We are collecting several
measures at session 1 and following up with similar measures during session 2 and
session 3. This information is being asked to determine your eligibility in our research
study, this information will not be used other than for the purposes of this research study.
If you decide not to participate or for some reason are ineligible to participate, this
information will be destroyed. Does this sound like something you would like to
participate in? (If no, thank the person for their time. If yes, ask the following screening
questions. If the potential subject is determined ineligible for any of the screening criteria
below, please provide the explanation for their ineligibility presented in italics below
each screening question.)
1. How old are you?__________________
If not between the ages of 65-85
[I am sorry at this time we are looking for subjects between the ages of 65-85, but thank
you for your time and interest]
2. How would you describe your ethnic background?____________________________
3. Do you have any assistive devices such as a pacemaker? Y

N

[I am sorry, we are unable to have people with any electrical assistive devices such as
yours, because it can send a false signal when measuring heart rate, but we thank you for
your time and interest]
4. Have you ever had a stroke or TIA (Transient ischemic attack, or “mini stroke”),
Y
N
Date:___________
[I am sorry, we are unable to have people who have had a stroke previously because a
stroke can affect measures that we are collecting, but we thank you for your time and
interest]
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5. Have you ever been diagnosed with arrhythmias (irregular heart rate) or vascular
dementia (loss of mental function due to interruption of blood flow to the brain such as a
stroke or heart attack)? Y
N
[Arrhythmia and vascular dementia can interfere with the measures that we are
collecting.]
6. Are you currently taking any medication? Y

N

Which ones?_______________________________________________
not to be taking certain psychotropic medications (e.g., tricyclic antidepressants, selective
serotonin reuptake inhibitors (SSRI’s), anticonvulsants, or antipsychotics). [Some
medications can interfere with the measures we are taking, but thank you for your
interest and time]
7. Have you ever been diagnosed with cancer?

Y

N

Y

N

Were you under any treatment for cancer?

Y

N

Within the last year?

Y

N

Within the last year?

[Treatments for cancer can often interfere with the measures we are taking, so we are
unable to have you participate in the study, but thank you for your time and interest]
8. Have you ever been diagnosed with Kidney or Liver Disease?

Y

N

[Certain illnesses and diseases may interfere with nerve conduction in some of the
measures we are collecting]
9. Have you ever been diagnosed with a neurological illness? (ex. Multiple sclerosis or
Parkinson’s Disease)
Y
N
[Certain illnesses and diseases may interfere with nerve conduction in some of the
measures we are collecting]
10. Do you suffer from significant hearing, sight, or sensory impairment? Y

N

Please describe:________________________________________________________
_____________________________________________________________________
[Impairment of vision, hearing, and other sensory functions may interfere with your
ability to complete the testing required for this study]
11. How far did you get in school? _____________
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12. Have you ever been hospitalized for a psychiatric problem?
Have you ever been diagnosed with a psychiatric illness?

Y

N

Which one?_______________________________________________
When?___________________________________________________
Were you given any medications for treatment?

Y

N

Which ones?_______________________________________________
Must have no lifetime history of certain psychiatric symptoms or illnesses (including
psychotic or delusional symptoms, bipolar disorder and schizophrenia).
[Unfortunately we are unable to accept people who suffer from these diseases due to the
possible interference in the measures we collect during the study]
13. On average about how many alcoholic beverages do you consume in a week? ______
(One beverage is equal to a 12oz. beer, 5 oz. Wine, or 1.5 oz of hard liquor)
14. Have you ever had a concussion or head injury?

Y

N

How many? _______________
When? ___________________
Is subject eligible?

Y

N

Yes: Well, Mr/Mrs. ___________ it appears you would be a good candidate for this
study, would you be able to come in for the first visit on________? At_______. This first
visit takes about 1 hour and 30 minutes to complete so please wear comfortable clothes.
You will come into our office and be given informed consent which details the study and
you can determine if the study is right for you. If you decided that you would like to
participate, you will at that time have a medical history interview and EKG. We will then
administer a series of neuropsychological tests. [Be sure to gather home contact
information]
No: I am sorry but you are not eligible at this time to participate in this study. We
appreciate your time and interest.
Criteria:
a) Meets age criteria and reports no clinical history of severe and chronic diseases
affecting general health (cancer or treatment for cancer [within the past year],
neurological disorders [e.g., multiple sclerosis], chronic kidney or liver disease, stroke or
cerebrovascular events or disease)
b) Is fluent in English (i.e., have commonly used English in everyday speaking and
reading for at least 10 years)
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c) Has no electronic assistive devices that may interfere with measuring HRV
d) Does not have current substance dependence
e) Is not taking certain psychotropic medications (e.g., tricyclic antidepressants,
anticonvulsants, or antipsychotics)
f) Has no lifetime history of certain psychiatric symptoms or illnesses (including
psychotic or delusional symptoms, bipolar disorder and schizophrenia)
g) Does not suffer from significant hearing, sight, or sensory impairment
h) Has no history of arrhythmias or vascular dementia
i) Has not sustained any significant head trauma that may impair cognitive function
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APPENDIX B
Demographics/Socioeconomic Status Form
A. PERSONAL INFORMATION (Please circle)
1.

Sex:
(1) Male
(2) Female

2.

Age:

________

3.

Date of birth: _____/______/_____
mm

4.

5.

dd

yy

Racial categories:
(1)

Caucasian, white

(2)

African American, black

(3)

Asian

(4)

Latino or Hispanic

(5)

Native American

(6)
(6)

Bi- or multiracial, please specify: _________________
Other, please specify: __________________________

What is your current marital status?
(1)

Married/living with partner

(2)

Widowed

(3)

Separated

(4)

Divorced

(5)

Single
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6.
Total family income (before taxes; including your income and your spouse or
partner’s income):

7.

(1)

Less than $10,000/year

or

$0 - 833/month

(2)

$10,000 - 14,999/year

or

$834- 1249/month

(3)

$15,000 - 24,999/year

or

$1250 - 2083/month

(4)

$25,000 - 34,999/year

or

$2084 - 2916/month

(5)

$35,000 - 49,999/year

or

$2917 - 4166/month

(6)

$50,000 - 64,999/year

or

$4167 - 5416/month

(7)

$65,000 - 79,999/year

or

$5417 - 6666/month

(8)

$80,000 - 94,999/year

or

$6667 - 7916/month

(9)

$95,000 - 109,999/year

or

$7917 - 9167/month

(10)

$110,000 - 125,000/year

or

$9168 - 10,416/month

(11)

More than $125,000/year

or

more than 10,417/month

Individual income (before taxes):

(1)

Less than $10,000/year

or

$0 - 833/month

(2)

$10,000 - 14,999/year

or

$834- 1249/month

(3)

$15,000 - 24,999/year

or

$1250- 2083/month

(4)

$25,000 - 34,999/year

or

$2084-2916/month

(5)

$35,000 - 49,999/year

or

$2917- 4166/month

(6)

$50,000 - 64,999/year

or

$4167 - 5416/month

(7)

$65,000 - 79,999/year

or

$5417 - 6666/month

(8)

$80,000 - 94,999/year

or

$6667 - 7916/month

(9)

$95,000 - 109,999/year

or

$7917 - 9167/month

(10)

$110,000 - 125,000/year

or

$9168 - 10,416/month

(11)

More than $125,000/year

or

more than 10,417/month
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B.

EDUCATION/OCCUPATION

8.

How far did you get in school?
a. Specify number of years attended school (PLEASE CIRCLE): This refers to
the number of
full time (8-9 month) years of school.

GRADE SCHOOL

1

2

3

4

HIGH SCHOOL

5

6

7

8

9

COLLEGE

13

14

15

10

11

12

POST GRADUATE

16

17

18

19

20

21

b. Education level (please circle highest level achieved/completed):

(0)No High School diploma
(1)GED
(2)High School diploma
(3)Technical training
(4)Some college, no degree
(5)Associate degree
(6)Bachelors degree
(7)Masters degree
(8)MD/PhD/J.D./PharmD

22

23

24+
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10.
What kind of work do you do? (i.e., What is/was your job? Do you work outside
of your home)?
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________
Main occupation - if not working due to retirement, disability, or unemployment but
worked at least 6 months in past 12 months [at 1 or more jobs] ask job questions about
most recent job.
11. Do you own your own business (or are you self-employed)?
Yes

No

12.
If currently employed, how many hours a week do/did you work? ________
hours
1 = FT (>= 35 hours/week)
2 = PT (1-34 hours/week)

13.

How long have you/did you work in that occupation or profession?
_________ years

__________ months
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APPENDIX C
Lifestyle Behaviors Questionnaire Form
1. How many caffeinated beverages (coffee, tea, sodas, etc.) do you consume each day?
_________
(daily total)

2. Have you ever used any of the following tobacco products?
a. Cigarettes:

No

Yes _________
(# of years)

Currently _________
(# of years)

Quit_______
(year quit)

b. Pipe:

No

Yes _________
(# of years)

Currently _________
(# of years)

Quit_______
(year quit)

c. Cigar:

No

Yes _________
(# of years)

Currently _________
(# of years)

Quit_______
(year quit)

d. Chewing tobacco: No

Yes _________
(# of years)

Currently ______
(# of years)

Quit_______
(year quit)

e. Snuff : Never

Occasionally or tried

Regular Use (# of yrs) ______

3. On average about how many alcoholic beverages do you consume in a week?
________
(One beverage is equal to a 12oz. beer, 5 oz. Wine, or 1.5 oz of hard liquor)
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4. Did you drink any alcohol in the last week?

NO

YES

4a. We would like to know the number of alcoholic drinks you have
had in the last week. Today is __________. Let’s begin with yesterday.
BEER

WINE

LIQUOR

OTHER (SPECIFY)

M

_____

_____

_____

_____________

T

_____

_____

_____

_____________

W

_____

_____

_____

_____________

R

_____

_____

_____

_____________

F

_____

_____

_____

_____________

SA

_____

_____

_____

_____________

SU

_____

_____

_____

_____________
____________
(7 day total)

5. At least once a week, do you engage in regular activity such as brisk walking, jogging,
bicycling, swimming, etc., long enough to work up a sweat, get your heart thumping, or
get out of breath?
____ No. Why not?
__________________________________________________

____ Yes.

How many times per week? _______

In what type of activities do you engage? _________________
6. Approximately how many hours do you spend each week participating in physical
activities such as walking, playing a sport, ( golf, tennis, etc.), physical therapy, or group
exercises such as water aerobics?
__________
(number of hours)
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APPENDIX D
Medical History Checklist Form
Do you have or have you had any of the following? (PLEASE CHECK ONE)

YES

NO

(1)

(0)

DON’T
KNOW
(-3)

Heart or Blood Vessels
1. High blood pressure (hypertension)

( )

( )

( )

2. Heart attack (myocardial infarction, coronary occlusion or
coronary thrombosis)

( )

( )

( )

3. Angina (chest pain brought on by exertion)

( )

( )

( )

4. Heart bypass surgery

( )

( )

( )

5. Heart balloon angioplasty, stent

( )

( )

( )

6. Congestive heart failure

( )

( )

( )

7. Valve problems (heart murmur or leaky valve)

( )

( )

( )

8. Heart pacemaker

( )

( )

( )

9. Rheumatic fever with involvement of heart

( )

( )

( )

10. Abnormal heart rhythm (e.g. atrial fibrillation)

( )

( )

( )

11. Other (Specify: _______________________________)

( )

( )

( )

Brain
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12. Stroke (cerebrovascular accident)

( )

( )

( )

13. TIA or transient ischemic attack (brief stroke that completely
resolved within 24 hours)

( )

( )

( )

14. Convulsions, fits or seizures, epilepsy

( )

( )

( )

15. Head injury or concussion or spinal cord injury, how many?

( )

( )

( )

16. Loss of consciousness, how long?

( )

( )

( )

17. Parkinson’s disease, Multiple Sclerosis or Muscular
Dystrophy

( )

( )

( )

18. Other (Specify:________________________________)

( )

( )

( )

YES

NO

DON’T
KNOW

(1)

(0)

Other Diseases

(-3)

19. Diabetes (high blood or urine sugar)

( )

( )

( )

20. Kidney problems (nephritis, kidney infection, kidney stones)

( )

( )

( )

21. Surgery (type: ______________________________)

( )

( )

( )

22. Cancer (site:___________________________)

( )

( )

( )

23. Asthma

( )

( )

( )

24. Other lung problems (TB, emphysema, pleurisy, chronic
bronchitis, or other problems)

( )

( )

( )

25. Thyroid condition

( )

( )

( )

26. Liver disease (hepatitis, cirrhosis or other problems)

( )

( )

( )
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27. Arthritis

( )

( )

( )

28. Hives, hay fever, or other allergies

( )

( )

( )

29. Other major disease (specify: ________________________)

( )

( )

( )

30. Have you ever been hospitalized?

( )

( )

( )

Please indicate whether the following are true:

YES

NO

(1)

(0)

31. Full use of arms, hands, and fingers

( )

( )

32. Full use of legs and feet

( )

( )

33. Good eyesight (when wearing glasses or contact lens)

( )

( )
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APPENDIX E
Medication Update Form

1. Are you currently taking Aricept (donepezil)? Yes_____
1a. If so how much do you take?

No_____

__________(mg)

1b. How often do you take Aricept? (twice a day, once a day, etc.)
______________________________________________________
______________________________________________________
______________________________________________________

1c. What time did you last take Aricept? (this morning, last night, etc.)
_______________________________________________________
_______________________________________________________
_______________________________________________________

Note any change in dosage or instructions for administration here.
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
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2. Are you currently taking any other medications that require a prescription from a
doctor?
Yes _____ No______
Medication Name

Purpose

Dosage (mg) and
Frequency

Last taken

2. Do you take any supplements or over the counter medications?
(For example, a multiple vitamin, vitamin C, calcium, iron, St. John’s wort,
glucosamine, ginkgo, allergy
pill, cold medication, antacid or , laxative)
Yes_____

No_____

Supplement Name

Dosage (mg) and
Frequency

Last taken
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3.
Since your last session, have you taken aspirin or an over-the-counter pain
medications
(ibuprofen, Tylenol, etc)?

Yes_____ No_____

Medication Name

Purpose

Dosage (mg) and
Frequency

Last taken

Notes:
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
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APPENDIX F
Physical and Biological Assessments
Height: __________
Weight: __________
Blood Pressure
Cuff Size:

_________

1st:

_________

2nd:

_________

HRV measurement:
Time: __________
Date: __________

Respiration:
Minute 1:
Total Rate for minute:

___________

Minute 3:
Total Rate for minute:

___________

Average of two readings:

___________

• Divide by 60:

___________

• ADD (0.03)

___________

• SUBTRACT (0.03) ___________
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APPENDIX G
Power Analysis
Supine:
F tests - ANOVA: Repeated measures, between factors
Analysis: A priori: Compute required sample size
Input:
Effect size f
= 0.82
α err prob
= 0.05
Power (1-β err prob)
= 0.80
Number of groups
= 2
Repetitions
= 3
Corr among rep measures
= 0.5
Output: Noncentrality parameter λ = 12.103200
Critical F
= 4.964603
Numerator df
= 1.000000
Denominator df
= 10.000000
Total sample size
= 12
Actual power
= 0.879100

Standing:
F tests - ANOVA: Repeated measures, between factors
Analysis: A priori: Compute required sample size
Input:
Effect size f
= 0.65
α err prob
= 0.05
Power (1-β err prob)
= 0.80
Number of groups
= 2
Repetitions
= 3
Corr among rep measures
= 0.5
Output: Noncentrality parameter λ = 10.140000
Critical F
= 4.600110
Numerator df
= 1.000000
Denominator df
= 14.000000
Total sample size
= 16
Actual power
= 0.841313
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